Track market-moving stories before they get noisy

Axxcess Wealth Management LLC lessened its stake in Johnson & Johnson (NYSE:JNJ – Free Report) by 44.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,379 shares of the company’s stock after selling 39,667 shares during the period. Axxcess Wealth Management LLC’s holdings in Johnson & Johnson were worth $13,337,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Outlook Capital Management LLC acquired a new stake in Johnson & Johnson during the second quarter valued at $28,000. Matrix Trust Co raised its position in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after acquiring an additional 54 shares during the period. Montgomery Financial Services LLC acquired a new position in shares of Johnson & Johnson in the second quarter worth about $43,000. Polaris Financial Partners purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $56,000. Finally, Bullseye Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $63,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance Shares of JNJ opened at $264.13 on Friday. The stock has a market cap of $635.85 billion, a PE ratio of 40.02, a price-to-earnings-growth ratio of 2.65 and a beta of 0.21. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07. The firm has a fifty day moving average price of $265.64 and a 200 day moving average price of $250.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year. Johnson & Johnson Announces Dividend The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio is 81.21%.

Insider Activity In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the company’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 64,515 shares of company stock worth $17,271,766 in the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Key Stories Impacting Johnson & Johnson Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J’s oral psoriasis pill Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns Analyst Upgrades and Downgrades JNJ has been the subject of several recent analyst reports. Morgan Stanley cut their price target on Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating for the company in a research note on Thursday, October 15th. Raymond James Financial set a $280.00 price target on Johnson & Johnson in a research report on Monday, August 3rd. Johnson Rice downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday. Argus set a $300.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 29th. Finally, Freedom Capital upgraded shares of Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $275.92.

View Our Latest Research Report on Johnson & Johnson

Johnson & Johnson Company Profile (Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Further Reading Five stocks we like better than Johnson & Johnson Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Cooke & Bieler LP reduced its stake in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 68.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 80,499 shares of the company’s stock after selling 174,820 shares during the period. Cooke & Bieler LP’s holdings in Johnson & Johnson were worth $21,311,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wavvest Wealth LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $542,000. Kraft Davis & Associates LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter worth about $212,000. Strengthening Families & Communities LLC grew its holdings in shares of Johnson & Johnson by 3.1% in the 3rd quarter. Strengthening Families & Communities LLC now owns 22,144 shares of the company’s stock worth $5,862,000 after purchasing an additional 663 shares during the last quarter. Sawyer & Company Inc acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $3,792,000. Finally, City State Bank lifted its holdings in Johnson & Johnson by 0.4% during the 3rd quarter. City State Bank now owns 11,275 shares of the company’s stock valued at $2,985,000 after purchasing an additional 41 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes Several brokerages have recently commented on JNJ. Citigroup increased their target price on Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Raymond James Financial set a $280.00 price target on shares of Johnson & Johnson in a research report on Monday, August 3rd. Scotiabank reissued an “outperform” rating and set a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Leerink Partners lowered their price objective on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating for the company in a research report on Wednesday, October 14th. Finally, Weiss Ratings raised shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $275.92.

Get Our Latest Research Report on Johnson & Johnson Johnson & Johnson News Summary Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J’s oral psoriasis pill Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns Insider Buying and Selling In related news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Jennifer Taubert sold 15,000 shares of the business’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 64,515 shares of company stock valued at $17,271,766. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Down 1.3% Johnson & Johnson stock opened at $264.13 on Friday. The company’s 50 day simple moving average is $265.64 and its 200 day simple moving average is $250.21. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07. The firm has a market capitalization of $635.85 billion, a price-to-earnings ratio of 40.02, a PEG ratio of 2.65 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last issued its earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating the consensus estimate of $2.53 by $0.06. The firm had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business’s quarterly revenue was up 5.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Johnson & Johnson Profile (Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Read More Five stocks we like better than Johnson & Johnson Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

In 24 heavily pre-treated patients with advanced primary cutaneous melanoma whose cancer had progressed after multiple prior lines of therapy including anti-PD-1 therapy, data continue to show an acceptable safety profile and early signals of efficacy 41.7% (10/24) overall response rate (ORR) per RECIST 1.1, including 4 complete responses75% (18/24) disease control rate (DCR)17.8 months median Overall SurvivalExploratory analysis in a subset of patients (n=8) identified IL-1β, a cytokine linked to treatment-induced anti-tumor immunity, as the most increased plasma cytokine after treatmentInvestigators concluded that these preliminary findings warrant further evaluation in randomized clinical trials for patients with primary cutaneous melanoma naïve or refractory to anti-PD-1 Data presented at the 2026 Congress of the European Society for Medical Oncology

PARIS and CAMBRIDGE, Mass., Oct. 24, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced updated results from patients with anti-PD-1-resistant advanced primary cutaneous melanoma treated in the ongoing Phase 1 Study 1100. The study evaluates JNJ-1900 (NBTXR3), which works in the presence of radiotherapy, followed by an immune checkpoint inhibitor (nivolumab or pembrolizumab) in patients with advanced solid tumors. The data were presented by Jason Chan, MD, Associate Professor, Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, in a poster session on Saturday, October 24, 2026, at the 2026 Annual Meeting of the European Society for Medical Oncology (“ESMO”) in Madrid, Spain.

ABSTRACT #3956: Safety and Anti-Tumor Activity of NBTXR3/SBRT with Immune Checkpoint Inhibitors in Anti-PD-1 Resistant Melanoma: Results from a Phase I Dose Expansion

J. Chan, J. Lee, A. Lam, A. Daud, F. Collichio, H. Yu, P. Mody, J. Weiss, S. Moschos, S. Powell, S. Peck, M. Lohr, E. Redstone, Z. Li, W. Smith, A. Juloori, R. Gineste, D. Rolando, A. Rosenberg and C. Shen. UCSF Helen Diller Family Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill; Sanford Cancer Center; St Luke's University Hospital; The University of Chicago; Nanobiotix

Patients with advanced anti-PD-1 resistant primary cutaneous melanoma whose disease has progressed after multiple prior lines of therapy have a poor prognosis; published series report a median progression-free survival of approximately three months1 and a median overall survival of approximately one year2 in this setting. Melanoma has historically been considered radioresistant, and higher radiation doses are often limited by exposure of the surrounding healthy tissue.

“Patients whose melanoma has progressed on anti-PD-1 therapy, and often on several other immunotherapies as well, have limited options left,” said Jason Chan, MD, Associate Professor, Department of Radiation Oncology, UCSF Helen Diller Family Comprehensive Cancer Center “In this study, a single injection followed by a short course of stereotactic radiotherapy was feasible across a wide range of tumor sizes and locations, and we saw responses in lesions that were injected and in lesions that were not. The observed increase in IL-1β suggests treatment-related immune activation that warrants further investigation. These are early data from a single-arm study, and they support testing the approach in a randomized trial.”

All 24 heavily pre-treated patients had advanced primary cutaneous melanoma resistant to anti-PD-1; 14 had stage IV disease. Most had received other immunotherapies before enrolling, including anti-CTLA-4 (50%), anti-LAG-3 (33.3%) and T-VEC (25%), and 87.5% had received immunotherapy as their most recent therapy. Patients received a one-time intratumoral injection of JNJ-1900 (NBTXR3) at the recommended Phase 2 dose (33% of gross tumor volume), followed by stereotactic body radiotherapy (“SBRT”) to the injected lesion and then nivolumab or pembrolizumab. Investigators observed an acceptable safety profile and early signals of efficacy.

Safety and Feasibility

Treatment consisting of a single intratumoral JNJ-1900 (NBTXR3) injection, followed by a short course of radiotherapy was feasible across a wide range of melanoma lesions, providing a minimally invasive treatment approach with an acceptable safety profile. No new safety signals have been observed.

Preliminary Efficacy

An Overall Response Rate (ORR) of 41.7% (10/24 patients) was observed. Responses were observed in both injected (ORR 45.8%; 11/24 evaluable patients) and non-injected lesions (ORR 30.0%; 3/10 evaluable patients).

Median Progression Free Survival (PFS) was 6.9 months, while median Overall Survival reached 17.8 months.

Exploratory Immune Profiling

In an exploratory analysis of plasma samples from a subset of patients (n=8), IL-1β showed the largest increase from baseline among the cytokines evaluated. Published research has linked IL-1β to treatment-induced anti-tumor immunity through its role in connecting innate immune activation to the priming of tumor-specific CD8+ T cells.3

"This updated analysis, with more patients and longer follow-up, builds on the first data we reported with consistent safety and an improvement in Overall Survival relative to the first data reported," said Louis Kayitalire, MD, Chief Medical Officer of Nanobiotix. "Responses were again seen in patients whose disease had progressed after multiple prior therapies, including in lesions that were not injected. Together with the exploratory cytokine data, these findings warrant further evaluation of JNJ-1900 (NBTXR3) followed by anti-PD-1 therapy in patients with anti-PD-1-resistant melanoma."

Overall, the acceptable safety profile and early efficacy observed by investigators in these preliminary findings provide promising signals of activity and warrant further evaluation in larger randomized trials.

About JNJ-1900 (NBTXR3)

JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and designed to work in the presenced of radiotherapy. The product candidate’s mechanism of action (MoA) is designed to induce significant tumor cell death in the injected tumor when in the presence of radiotherapy, subsequently triggering adaptive immune response and long-term anti-cancer memory. Proof-of-concept was demonstrated in a randomized Phase 2/3 soft tissue sarcoma study sponsored by Nanobiotix in 2018.

JNJ-1900 (NBTXR3) is being evaluated across multiple solid tumor indications as a single agent or combination therapy. Given the Company’s focus areas, and balanced against the scalable potential of NBTXR3, Nanobiotix has engaged in a collaboration strategy to expand development of the product candidate in parallel with its priority development pathways. Pursuant to this strategy, in 2019 Nanobiotix entered into a broad, comprehensive clinical research collaboration with The University of Texas MD Anderson Cancer Center to sponsor several Phase 1 and Phase 2 studies evaluating JNJ-1900 (NBTXR3) across tumor types and therapeutic combinations.

In February 2020, the United States Food and Drug Administration granted regulatory Fast Track designation for the investigation of NBTXR3 with or without cetuximab, for the treatment of patients with locally advanced HNSCC who are not eligible for platinum-based chemotherapy.

In 2023, Nanobiotix announced a license agreement for the global development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company. Studies being led by Johnson & Johnson include NANORAY-312 (NCT04892173), a global, randomized Phase 3 study in platinum-based chemotherapy-ineligible, locally advanced head and neck squamous cell cancers; LUMIRAY (NCT07219212), a global, phase 1b, open-label study in locally advanced head and neck squamous cell cancers; and CONVERGE (NCT06667908), a phase 2, randomized, open-label, active-controlled study in locally advanced and unresectable Stage III non-small cell lung cancer (NSCLC).

About NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter

Disclaimer

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations. Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements which are based on the Company’ management’s current expectations and assumptions and on information currently available to management. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized. Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on March 31, 2026 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2025 universal registration document filed with the AMF on March 31, 2026 under “chapter 1.5 Risk Factors”, and subsequent filings Nanobiotix makes with the SEC and AMF from time to time, including the Half-Year Report at June 30, 2026, which are available on the SEC’s website at www.sec.gov and on the AMF's website at www.amf.org, The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements publicly.

Nanobiotix Communications Department
Brandon Owens
VP, Communications
[email protected]
Investor Relations Department
Joanne Choi
VP, Investor Relations (US)
[email protected] Ricky Bhajun
Director, Investor Relations (EU)

[email protected] Media Relations 
France – HARDY
Caroline Hardy
+33 06 70 33 49 50
[email protected]
Global – uncapped
Becky Lauer
+1 (646) 286-0057
[email protected]   ________________ 

1Patrinely JR Jr., Cancer. 2020
2Nordstrom BL, Future Oncol. 18:1343-1355, 2022
3Ghiringhelli et al. Nat Med. 15(10):1170-8, 2009

PR_Study 1100 Melanoma Data ESMO 2026

CMH Wealth Management LLC acquired a new position in shares of ExxonMobil Corporation (NYSE:XOM – Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 18,909 shares of the oil and gas company’s stock, valued at approximately $3,077,000.

A number of other institutional investors also recently added to or reduced their stakes in XOM. GQG Partners LLC raised its holdings in ExxonMobil by 153.3% in the second quarter. GQG Partners LLC now owns 16,877,523 shares of the oil and gas company’s stock worth $2,307,497,000 after purchasing an additional 10,214,420 shares in the last quarter. Quantum Portfolio Management LLC purchased a new stake in ExxonMobil during the first quarter valued at approximately $965,932,000. Arrowstreet Capital Limited Partnership purchased a new stake in ExxonMobil during the first quarter valued at approximately $766,345,000. Diamant Asset Management Inc. boosted its stake in ExxonMobil by 17,312.4% in the first quarter. Diamant Asset Management Inc. now owns 2,183,864 shares of the oil and gas company’s stock valued at $370,514,000 after acquiring an additional 2,171,322 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in ExxonMobil by 5.7% in the first quarter. Dimensional Fund Advisors LP now owns 28,364,314 shares of the oil and gas company’s stock valued at $4,812,790,000 after acquiring an additional 1,540,902 shares in the last quarter. Institutional investors own 61.80% of the company’s stock.

Analyst Upgrades and Downgrades Several research firms have issued reports on XOM. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $182.00 price target on shares of ExxonMobil in a report on Thursday, October 1st. Royal Bank Of Canada reiterated a “sector perform” rating and set a $180.00 price objective (up from $160.00) on shares of ExxonMobil in a report on Monday, September 21st. The Goldman Sachs Group reissued a “neutral” rating and issued a $178.00 price objective on shares of ExxonMobil in a research report on Tuesday. Freedom Capital upgraded ExxonMobil from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Finally, UBS Group reaffirmed a “buy” rating and set a $199.00 target price on shares of ExxonMobil in a research report on Monday. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and thirteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $167.70.

Read Our Latest Analysis on ExxonMobil Key Headlines Impacting ExxonMobil Here are the key news stories impacting ExxonMobil this week:

Positive Sentiment: Upcoming earnings may provide support: Wall Street expects ExxonMobil to report year-over-year earnings growth next week, and Zacks says the company has factors that could support a potential earnings beat. Exxon Mobil Holdings Reports Next Week Positive Sentiment: Analyst estimates moved higher: Erste Group raised its FY2027 EPS forecast to $11.81 from $11.12, signaling improving expectations for ExxonMobil’s future earnings power. ExxonMobil analyst estimate report Positive Sentiment: Oil prices and upstream assets remain favorable: ExxonMobil’s low-cost Permian and Guyana operations are viewed as supporting production growth toward its 2030 ambitions. Higher crude prices, including Brent above $100 per barrel after Middle East attacks, have helped drive the stock’s recent gains. ExxonMobil long-term upstream production Positive Sentiment: Dividend and balance-sheet appeal: ExxonMobil is highlighted among mega-cap companies with a long record of raising payouts through different economic and interest-rate environments. Analysts also cite its stronger balance sheet relative to BP, while momentum-focused coverage points to continued investor interest. Dividend stocks with long payout records Neutral Sentiment: Valuation and relative-performance debate: ExxonMobil has substantially outperformed this year and compares favorably with BP on gains and financial strength, but analysts give Chevron an edge for further upside based on free cash flow, cost savings and projected 2026 earnings growth. Chevron versus ExxonMobil Negative Sentiment: Illinois refinery disruption: An issue at ExxonMobil’s Joliet refinery is contributing to higher gasoline prices in the Chicago area and could pressure near-term refinery operations, although the wider market impact remains uncertain. Midwest pump prices surge after Illinois refinery disruption ExxonMobil Stock Up 2.8% ExxonMobil stock opened at $183.23 on Friday. The business’s 50-day simple moving average is $165.80 and its two-hundred day simple moving average is $155.09. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.85 and a current ratio of 1.13. The company has a market cap of $759.46 billion, a PE ratio of 23.58, a PEG ratio of 0.89 and a beta of 0.21. ExxonMobil Corporation has a fifty-two week low of $112.51 and a fifty-two week high of $183.75.

ExxonMobil (NYSE:XOM – Get Free Report) last announced its quarterly earnings data on Friday, July 31st. The oil and gas company reported $3.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.56 by ($0.04). ExxonMobil had a return on equity of 13.14% and a net margin of 8.88%. The firm had revenue of $114.53 billion during the quarter, compared to analysts’ expectations of $109.94 billion. During the same quarter in the previous year, the business earned $1.64 earnings per share. Equities analysts anticipate that ExxonMobil Corporation will post 13.63 EPS for the current year.

ExxonMobil Dividend Announcement The firm also recently declared a quarterly dividend, which was paid on Thursday, September 10th. Investors of record on Monday, August 17th were issued a $1.03 dividend. This represents a $4.12 annualized dividend and a yield of 2.2%. The ex-dividend date was Monday, August 17th. ExxonMobil’s dividend payout ratio is 53.02%.

ExxonMobil Company Profile (Free Report)

Exxon Mobil Corporation, doing business as ExxonMobil (NYSE:XOM), is an integrated energy company engaged in the exploration, development, production, and sale of crude oil and natural gas. Its operations span the energy value chain, from resource development and refining to the marketing and distribution of fuels and other energy products.

Through its Energy Products segment, ExxonMobil manufactures and markets transportation fuels, lubricants, and other petroleum-based products. Its Chemical Products business produces petrochemicals, including commodity and performance products used in packaging, automotive components, construction materials, and consumer goods.

Read More Five stocks we like better than ExxonMobil Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for ExxonMobil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ExxonMobil and related companies with MarketBeat.com's FREE daily email newsletter.

Adams Natural Resources Fund Inc. cut its stake in shares of ExxonMobil Corporation (NYSE:XOM – Free Report) by 0.9% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,334,355 shares of the oil and gas company’s stock after selling 12,000 shares during the period. ExxonMobil accounts for 24.1% of Adams Natural Resources Fund Inc.’s holdings, making the stock its largest position. Adams Natural Resources Fund Inc.’s holdings in ExxonMobil were worth $217,166,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Aventus Investment Advisors Inc. acquired a new position in ExxonMobil in the 2nd quarter valued at approximately $27,000. Portus Wealth Advisors LLC bought a new stake in shares of ExxonMobil in the 1st quarter worth approximately $36,000. Atlantic Private Wealth LLC raised its stake in shares of ExxonMobil by 776.9% during the 1st quarter. Atlantic Private Wealth LLC now owns 228 shares of the oil and gas company’s stock valued at $39,000 after purchasing an additional 202 shares during the period. Financial Connections Group Inc. purchased a new position in shares of ExxonMobil during the 1st quarter valued at $53,000. Finally, Clal Insurance Enterprises Holdings Ltd raised its position in shares of ExxonMobil by 53.1% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 326 shares of the oil and gas company’s stock valued at $55,000 after buying an additional 113 shares in the last quarter. 61.80% of the stock is currently owned by institutional investors.

Key ExxonMobil News Here are the key news stories impacting ExxonMobil this week:

Positive Sentiment: Upcoming earnings may provide support: Wall Street expects ExxonMobil to report year-over-year earnings growth next week, and Zacks says the company has factors that could support a potential earnings beat. Exxon Mobil Holdings Reports Next Week Positive Sentiment: Analyst estimates moved higher: Erste Group raised its FY2027 EPS forecast to $11.81 from $11.12, signaling improving expectations for ExxonMobil’s future earnings power. ExxonMobil analyst estimate report Positive Sentiment: Oil prices and upstream assets remain favorable: ExxonMobil’s low-cost Permian and Guyana operations are viewed as supporting production growth toward its 2030 ambitions. Higher crude prices, including Brent above $100 per barrel after Middle East attacks, have helped drive the stock’s recent gains. ExxonMobil long-term upstream production Positive Sentiment: Dividend and balance-sheet appeal: ExxonMobil is highlighted among mega-cap companies with a long record of raising payouts through different economic and interest-rate environments. Analysts also cite its stronger balance sheet relative to BP, while momentum-focused coverage points to continued investor interest. Dividend stocks with long payout records Neutral Sentiment: Valuation and relative-performance debate: ExxonMobil has substantially outperformed this year and compares favorably with BP on gains and financial strength, but analysts give Chevron an edge for further upside based on free cash flow, cost savings and projected 2026 earnings growth. Chevron versus ExxonMobil Negative Sentiment: Illinois refinery disruption: An issue at ExxonMobil’s Joliet refinery is contributing to higher gasoline prices in the Chicago area and could pressure near-term refinery operations, although the wider market impact remains uncertain. Midwest pump prices surge after Illinois refinery disruption Wall Street Analysts Forecast Growth Several research analysts have recently issued reports on the stock. DZ Bank cut shares of ExxonMobil from a “buy” rating to a “hold” rating and set a $156.00 target price on the stock. in a report on Tuesday, August 4th. Weiss Ratings raised ExxonMobil from a “buy (b-)” rating to a “buy (b)” rating in a research report on Tuesday, September 29th. Wells Fargo & Company restated an “equal weight” rating and issued a $182.00 price objective on shares of ExxonMobil in a research note on Thursday, October 1st. Morgan Stanley lifted their target price on ExxonMobil from $177.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, October 15th. Finally, Freedom Capital raised ExxonMobil from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and thirteen have assigned a Hold rating to the company’s stock. According to MarketBeat, ExxonMobil presently has a consensus rating of “Moderate Buy” and an average price target of $167.70. Get Our Latest Research Report on ExxonMobil

ExxonMobil Stock Up 2.8% Shares of NYSE:XOM opened at $183.23 on Friday. The business’s 50 day moving average is $165.80 and its 200 day moving average is $155.09. The company has a quick ratio of 0.85, a current ratio of 1.13 and a debt-to-equity ratio of 0.12. The stock has a market cap of $759.46 billion, a P/E ratio of 23.58, a price-to-earnings-growth ratio of 0.89 and a beta of 0.21. ExxonMobil Corporation has a 52-week low of $112.51 and a 52-week high of $183.75.

ExxonMobil (NYSE:XOM – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The oil and gas company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.56 by ($0.04). The firm had revenue of $114.53 billion for the quarter, compared to the consensus estimate of $109.94 billion. ExxonMobil had a return on equity of 13.14% and a net margin of 8.88%. During the same quarter last year, the firm earned $1.64 EPS. Sell-side analysts predict that ExxonMobil Corporation will post 13.63 EPS for the current year.

ExxonMobil Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Stockholders of record on Monday, August 17th were given a $1.03 dividend. The ex-dividend date was Monday, August 17th. This represents a $4.12 dividend on an annualized basis and a dividend yield of 2.2%. ExxonMobil’s payout ratio is 53.02%.

About ExxonMobil (Free Report)

Exxon Mobil Corporation, doing business as ExxonMobil (NYSE:XOM), is an integrated energy company engaged in the exploration, development, production, and sale of crude oil and natural gas. Its operations span the energy value chain, from resource development and refining to the marketing and distribution of fuels and other energy products.

Through its Energy Products segment, ExxonMobil manufactures and markets transportation fuels, lubricants, and other petroleum-based products. Its Chemical Products business produces petrochemicals, including commodity and performance products used in packaging, automotive components, construction materials, and consumer goods.

Further Reading Five stocks we like better than ExxonMobil Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat Want to see what other hedge funds are holding XOM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ExxonMobil Corporation (NYSE:XOM – Free Report).

Receive News & Ratings for ExxonMobil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ExxonMobil and related companies with MarketBeat.com's FREE daily email newsletter.

Andrew Hill Investment Advisors Inc. cut its stake in GE Aerospace (NYSE:GE – Free Report) by 68.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,597 shares of the company’s stock after selling 12,045 shares during the quarter. GE Aerospace comprises about 1.4% of Andrew Hill Investment Advisors Inc.’s investment portfolio, making the stock its 24th biggest position. Andrew Hill Investment Advisors Inc.’s holdings in GE Aerospace were worth $1,748,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. State Street Corp lifted its position in shares of GE Aerospace by 2.6% during the second quarter. State Street Corp now owns 46,497,628 shares of the company’s stock worth $17,377,559,000 after purchasing an additional 1,160,584 shares in the last quarter. Jennison Associates LLC boosted its position in GE Aerospace by 37.7% in the 1st quarter. Jennison Associates LLC now owns 11,026,006 shares of the company’s stock valued at $3,128,850,000 after buying an additional 3,017,937 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of GE Aerospace by 6.3% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,251,603 shares of the company’s stock valued at $2,710,142,000 after acquiring an additional 427,820 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of GE Aerospace by 97.3% during the second quarter. Wellington Management Group LLP now owns 6,797,935 shares of the company’s stock valued at $2,540,592,000 after acquiring an additional 3,352,432 shares in the last quarter. Finally, Bank of America Corp DE increased its position in shares of GE Aerospace by 10.0% during the first quarter. Bank of America Corp DE now owns 7,664,679 shares of the company’s stock worth $2,175,006,000 after acquiring an additional 695,731 shares during the last quarter. Institutional investors and hedge funds own 74.77% of the company’s stock.

Analysts Set New Price Targets GE has been the subject of a number of analyst reports. Weiss Ratings reissued a “buy (b)” rating on shares of GE Aerospace in a report on Thursday, October 15th. Citigroup restated a “buy” rating and set a $431.00 price objective (up from $353.00) on shares of GE Aerospace in a report on Wednesday, July 1st. HC Wainwright set a $375.00 target price on GE Aerospace in a research report on Wednesday. UBS Group reissued a “buy” rating and set a $380.00 price target (up from $377.00) on shares of GE Aerospace in a research report on Wednesday. Finally, JPMorgan Chase & Co. dropped their price target on shares of GE Aerospace from $400.00 to $375.00 and set an “overweight” rating for the company in a research note on Wednesday. Seventeen research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $373.52.

View Our Latest Report on GE GE Aerospace Stock Performance GE stock opened at $285.76 on Friday. The stock’s 50 day simple moving average is $322.95 and its 200 day simple moving average is $328.74. GE Aerospace has a 12-month low of $268.91 and a 12-month high of $388.84. The firm has a market cap of $295.29 billion, a P/E ratio of 32.96, a P/E/G ratio of 2.05 and a beta of 1.38. The company has a current ratio of 0.98, a quick ratio of 0.67 and a debt-to-equity ratio of 0.96.

GE Aerospace (NYSE:GE – Get Free Report) last issued its earnings results on Tuesday, October 20th. The company reported $2.25 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.24. GE Aerospace had a net margin of 17.31% and a return on equity of 44.43%. The company had revenue of $13.29 billion for the quarter, compared to analysts’ expectations of $12.88 billion. During the same period in the prior year, the company earned $1.66 earnings per share. The firm’s revenue was up 24.7% compared to the same quarter last year. As a group, equities research analysts predict that GE Aerospace will post 8.15 EPS for the current year.

GE Aerospace Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Monday, October 26th. Stockholders of record on Monday, October 5th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Monday, October 5th. GE Aerospace’s dividend payout ratio is presently 22.14%.

Trending Headlines about GE Aerospace Here are the key news stories impacting GE Aerospace this week:

Positive Sentiment: GE Aerospace beat third-quarter expectations for the eighth consecutive quarter, reporting adjusted EPS of $2.25 versus the $2.01 consensus and revenue of $13.29 billion, up 24.7% year over year. The company also raised its full-year guidance. GE Aerospace Reports Strong Earnings Again Positive Sentiment: Defense and Propulsion Technologies remains a bright spot, with revenue growth of 7% and orders up 18%, supported by military-engine demand and defense contracts. GE’s Defense & Propulsion Strength Seems Firm Positive Sentiment: Management expects to deliver more than 3,200 engines in South Asia over the next decade, highlighting a substantial long-term commercial opportunity. GE is also increasing engine deliveries as Boeing targets higher 787 production. GE Aerospace South Asia Engine Delivery Plans Neutral Sentiment: Several research reports remain bullish, citing strong aftermarket demand, execution improvements and GE’s leading position in aero engines. However, the stock’s elevated valuation means further gains may require continued earnings upgrades. Strong Aftermarket Demand and Improving Execution Negative Sentiment: Bernstein lowered its price target to $376 from $421, while Susquehanna, JPMorgan, BNP Paribas Exane and RBC also issued cautious views or reduced expectations. The cluster of target cuts is weighing on sentiment. Bernstein Lowers GE Aerospace Price Target Negative Sentiment: Analysts are concerned that high jet-fuel prices could pressure airline profitability and delay engine purchases. Investors are also factoring in projected 2027 transition costs associated with the GE9X production ramp, despite GE’s large services backlog. Why GE Aerospace Stock Keeps Going Down About GE Aerospace (Free Report)

GE Aerospace (NYSE: GE) is a global aerospace company that designs, develops, manufactures and services aircraft engines and related systems. Its products support commercial air transport, business and general aviation, military aircraft, and other defense applications. The company also provides engine components, avionics, mechanical systems, digital solutions and maintenance, repair and overhaul services.

GE Aerospace serves airlines, aircraft operators, leasing companies, airframers and government customers worldwide.

Read More Five stocks we like better than GE Aerospace Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat Want to see what other hedge funds are holding GE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE Aerospace (NYSE:GE – Free Report).

Receive News & Ratings for GE Aerospace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GE Aerospace and related companies with MarketBeat.com's FREE daily email newsletter.

BIP Wealth LLC trimmed its stake in shares of The Home Depot, Inc. (NYSE:HD – Free Report) by 17.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,957 shares of the home improvement retailer’s stock after selling 4,440 shares during the quarter. BIP Wealth LLC’s holdings in Home Depot were worth $5,962,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in HD. BlackRock Inc. acquired a new position in shares of Home Depot in the 2nd quarter valued at about $28,771,247,000. Bank of America Corp DE acquired a new stake in Home Depot during the second quarter worth approximately $5,780,468,000. Bank of New York Mellon Corp acquired a new position in shares of Home Depot during the 2nd quarter valued at $2,777,396,000. Corient Private Wealth LP acquired a new position in shares of Home Depot during the second quarter valued at about $390,913,000. Finally, Legal & General Group Plc acquired a new position in shares of Home Depot during the second quarter valued at about $1,953,883,000. 70.86% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling In related news, EVP Michael Rowe sold 710 shares of the business’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $336.76, for a total transaction of $239,099.60. Following the transaction, the executive vice president owned 6,838 shares in the company, valued at $2,302,764.88. The trade was a 9.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Teresa Roseborough sold 2,455 shares of Home Depot stock in a transaction on Friday, August 28th. The shares were sold at an average price of $328.77, for a total value of $807,130.35. Following the transaction, the executive vice president owned 14,061 shares of the company’s stock, valued at $4,622,834.97. The trade was a 14.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 9,829 shares of company stock worth $3,339,314 in the last ninety days. Corporate insiders own 0.08% of the company’s stock.

Wall Street Analysts Forecast Growth Several brokerages have recently commented on HD. Weiss Ratings restated a “hold (c)” rating on shares of Home Depot in a research note on Friday, October 2nd. Wells Fargo & Company increased their price objective on shares of Home Depot from $360.00 to $400.00 and gave the company an “overweight” rating in a research note on Tuesday, August 11th. Guggenheim reaffirmed a “buy” rating and issued a $425.00 price target on shares of Home Depot in a report on Wednesday, August 19th. KeyCorp reissued a “sector weight” rating on shares of Home Depot in a research report on Wednesday, August 19th. Finally, Royal Bank Of Canada cut their price objective on shares of Home Depot from $343.00 to $342.00 and set a “sector perform” rating for the company in a report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $375.93. Read Our Latest Analysis on HD

Home Depot Stock Performance Shares of HD opened at $319.73 on Friday. The company has a market cap of $318.99 billion, a PE ratio of 22.37, a price-to-earnings-growth ratio of 2.33 and a beta of 1.00. The company has a current ratio of 1.08, a quick ratio of 0.31 and a debt-to-equity ratio of 2.64. The stock has a 50-day moving average price of $309.69 and a 200-day moving average price of $323.89. The Home Depot, Inc. has a 12-month low of $277.15 and a 12-month high of $397.63.

Home Depot (NYSE:HD – Get Free Report) last announced its earnings results on Tuesday, August 18th. The home improvement retailer reported $4.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.73 by $0.19. The company had revenue of $47.86 billion during the quarter, compared to analyst estimates of $47.24 billion. Home Depot had a net margin of 8.41% and a return on equity of 106.42%. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the business earned $4.68 earnings per share. Home Depot has set its FY 2026 guidance at 14.690-15.278 EPS. As a group, equities analysts forecast that The Home Depot, Inc. will post 15.01 earnings per share for the current fiscal year.

Home Depot Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 17th. Stockholders of record on Thursday, September 3rd were paid a $2.33 dividend. The ex-dividend date of this dividend was Thursday, September 3rd. This represents a $9.32 dividend on an annualized basis and a dividend yield of 2.9%. Home Depot’s dividend payout ratio is 65.22%.

Key Headlines Impacting Home Depot Here are the key news stories impacting Home Depot this week:

Positive Sentiment: Home Depot is developing the “Orange Exchange,” a supplier initiative intended to connect the retailer with more small businesses. The effort could improve product quality, assortment and availability while supporting long-term customer demand. Home Depot’s latest move is good for customers and the U.S. economy Positive Sentiment: Recent coverage highlights potential support from lower interest rates, which could gradually stimulate home sales, remodeling activity and larger renovation projects. Home Depot stock rebounds as rate cuts stir home-improvement demand Positive Sentiment: Analyst earnings and revenue estimate revisions, along with the company’s growing distribution capabilities, have renewed attention on Home Depot’s valuation. The latest quarterly results also exceeded consensus expectations, with earnings of $4.92 per share and revenue of $47.86 billion. Positive Sentiment: Several major institutional investors increased their Home Depot holdings during the latest reported quarter, while the median analyst price target cited by Quiver Quantitative is $375, implying potential upside from recent trading levels. Neutral Sentiment: The Home Depot Foundation pledged $1 billion through 2032 for veteran housing and related causes. The announcement strengthens the company’s social-impact profile but is unlikely to materially affect near-term earnings. The Home Depot Foundation Pledges $1 Billion to Veteran Causes by 2032 Negative Sentiment: Risk-off trading, higher oil prices and persistently elevated mortgage rates are weighing on housing activity and economically sensitive retailers. Soft home sales and affordability concerns could delay big-ticket renovation demand. Negative Sentiment: Reported insider activity showed four sales and no purchases over the past six months, a potentially cautious signal, although the transactions do not necessarily indicate a change in the company’s fundamentals. Home Depot Company Profile (Free Report)

The Home Depot, Inc is a home improvement retailer serving do-it-yourself customers, professional contractors, and other building and maintenance professionals. The company sells a broad selection of building materials, hardware, tools, appliances, paint, plumbing and electrical supplies, flooring, lighting, lawn and garden products, and home décor.

In addition to merchandise, Home Depot offers services such as product delivery, tool and equipment rental, credit services, and installation for selected products.

Recommended Stories Five stocks we like better than Home Depot Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for Home Depot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Home Depot and related companies with MarketBeat.com's FREE daily email newsletter.

Brookstone Capital Management grew its stake in shares of The Goldman Sachs Group, Inc. (NYSE:GS – Free Report) by 8.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,636 shares of the investment management company’s stock after acquiring an additional 860 shares during the period. Brookstone Capital Management’s holdings in The Goldman Sachs Group were worth $9,576,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. Strive Financial Group LLC boosted its holdings in shares of The Goldman Sachs Group by 316.7% during the second quarter. Strive Financial Group LLC now owns 25 shares of the investment management company’s stock worth $25,000 after purchasing an additional 19 shares during the period. BOK Financial Private Wealth Inc. grew its position in shares of The Goldman Sachs Group by 188.9% in the 2nd quarter. BOK Financial Private Wealth Inc. now owns 26 shares of the investment management company’s stock worth $26,000 after buying an additional 17 shares during the period. Turim 21 Investimentos Ltda. bought a new position in shares of The Goldman Sachs Group during the first quarter valued at approximately $25,000. Cherry Tree Wealth Management LLC increased its position in The Goldman Sachs Group by 100.0% during the 3rd quarter. Cherry Tree Wealth Management LLC now owns 30 shares of the investment management company’s stock valued at $27,000 after buying an additional 15 shares in the last quarter. Finally, Clearstead Trust LLC purchased a new position in The Goldman Sachs Group during the second quarter valued at $33,000. 71.21% of the stock is currently owned by hedge funds and other institutional investors.

The Goldman Sachs Group Trading Down 1.7% GS stock opened at $876.07 on Friday. The company has a quick ratio of 0.63, a current ratio of 1.10 and a debt-to-equity ratio of 2.82. The Goldman Sachs Group, Inc. has a twelve month low of $754.00 and a twelve month high of $1,153.99. The stock has a market capitalization of $255.08 billion, a price-to-earnings ratio of 12.60, a price-to-earnings-growth ratio of 0.84 and a beta of 1.29. The firm’s fifty day simple moving average is $959.69 and its two-hundred day simple moving average is $990.65.

The Goldman Sachs Group (NYSE:GS – Get Free Report) last issued its quarterly earnings results on Tuesday, October 13th. The investment management company reported $17.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $12.86 by $4.15. The firm had revenue of $18.68 billion during the quarter, compared to analyst estimates of $16.83 billion. The Goldman Sachs Group had a return on equity of 19.55% and a net margin of 15.77%. The Goldman Sachs Group’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same period last year, the company earned $12.25 EPS. As a group, analysts anticipate that The Goldman Sachs Group, Inc. will post 70.89 earnings per share for the current year. The Goldman Sachs Group Dividend Announcement The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Wednesday, December 2nd will be given a dividend of $5.00 per share. The ex-dividend date of this dividend is Wednesday, December 2nd. This represents a $20.00 dividend on an annualized basis and a dividend yield of 2.3%. The Goldman Sachs Group’s dividend payout ratio (DPR) is 28.76%.

The Goldman Sachs Group News Roundup Here are the key news stories impacting The Goldman Sachs Group this week:

Positive Sentiment: Freedom Broker upgraded GS from “Hold” to “Buy” and set a $1,100 price target, implying approximately 25.6% upside from the referenced share price. However, the target was reduced from $1,200, which somewhat tempers the bullish signal. Freedom Broker upgrades Goldman Sachs to Buy Positive Sentiment: Goldman Sachs reported particularly strong equities performance in the third quarter, with net revenue rising 72% year over year to $6.44 billion. Robust client activity, financing demand and derivatives contributed to the result, supporting optimism about earnings momentum. Goldman Sachs equities revenue growth Positive Sentiment: Zacks upgraded Goldman Sachs to a Rank #2 (“Buy”), citing improving expectations for the company’s earnings prospects. Zacks upgrades Goldman Sachs to Buy Analysts Set New Price Targets A number of brokerages have recently issued reports on GS. BMO Capital Markets lowered their price target on The Goldman Sachs Group from $970.00 to $950.00 and set a “market perform” rating on the stock in a report on Monday, October 19th. Zacks Research downgraded The Goldman Sachs Group from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 18th. Wall Street Zen raised The Goldman Sachs Group from a “hold” rating to a “buy” rating in a report on Saturday. Evercore restated an “outperform” rating on shares of The Goldman Sachs Group in a research report on Monday, July 6th. Finally, HSBC raised their price objective on The Goldman Sachs Group from $995.00 to $1,007.00 and gave the stock a “hold” rating in a research note on Monday, September 28th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, The Goldman Sachs Group currently has an average rating of “Hold” and an average target price of $1,052.48.

Get Our Latest Stock Analysis on The Goldman Sachs Group

The Goldman Sachs Group Company Profile (Free Report)

The Goldman Sachs Group, Inc is a global financial services company that provides investment banking, securities, asset management and wealth management services to corporations, financial institutions, governments and individual investors. Its investment banking activities include advising on mergers and acquisitions, public and private offerings, restructurings and other strategic transactions.

Through its global markets businesses, Goldman Sachs helps clients buy and sell securities and other financial instruments and provides financing, risk management and market-making services.

Featured Articles Five stocks we like better than The Goldman Sachs Group Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat Want to see what other hedge funds are holding GS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Goldman Sachs Group, Inc. (NYSE:GS – Free Report).

Receive News & Ratings for The Goldman Sachs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Goldman Sachs Group and related companies with MarketBeat.com's FREE daily email newsletter.

Fifth Third Wealth Advisors LLC raised its stake in shares of Qualcomm Incorporated (NASDAQ:QCOM – Free Report) by 12.8% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 40,688 shares of the wireless technology company’s stock after buying an additional 4,602 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Qualcomm were worth $7,488,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Caitong International Asset Management Co. Ltd boosted its position in Qualcomm by 17,000.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 171 shares of the wireless technology company’s stock valued at $29,000 after purchasing an additional 170 shares during the last quarter. ABS Investment Management LLC acquired a new position in Qualcomm in the 2nd quarter worth about $34,000. ABS Direct Equity Fund LLC acquired a new position in Qualcomm in the 2nd quarter worth about $34,000. Your Advocates Ltd. LLP purchased a new stake in shares of Qualcomm during the 1st quarter worth about $26,000. Finally, Burk Holdings LLC raised its stake in shares of Qualcomm by 191.7% during the 2nd quarter. Burk Holdings LLC now owns 210 shares of the wireless technology company’s stock worth $39,000 after purchasing an additional 138 shares in the last quarter. 74.35% of the stock is currently owned by hedge funds and other institutional investors.

Qualcomm News Roundup Here are the key news stories impacting Qualcomm this week:

Positive Sentiment: ETFs recorded approximately $141.5 million in net Qualcomm purchases on Tuesday, followed by additional ETF buying reported for October 21. Passive and institutional demand can provide near-term support for QCOM. Qualcomm sees $141.5 million in net ETF buying Positive Sentiment: An analyst upgrade and a higher price target of $200 signal improving sentiment and suggest potential upside from current valuation levels. Qualcomm stock jumps on analyst upgrade Qualcomm price target raised to $200 Positive Sentiment: A bullish investment thesis argues Qualcomm is being undervalued as it builds businesses in automotive, data centers and custom silicon, potentially making it a longer-term artificial-intelligence beneficiary rather than solely a handset-chip company. This chip stock could be a sleeper AI winner Positive Sentiment: Qualcomm declared a quarterly dividend of $0.92 per share, or $3.68 annualized, representing an approximately 2.1% yield and reinforcing its shareholder-return appeal. Qualcomm declares quarterly dividend Neutral Sentiment: Qualcomm will release fiscal fourth-quarter and full-year 2026 results after the market closes on November 4. The report and guidance are the next major catalysts for the stock. Qualcomm schedules fiscal 2026 earnings release Neutral Sentiment: Coverage from 37 analysts highlights substantial investor attention ahead of earnings, while a valuation review says the shares are near fair value after strong long-term gains. Qualcomm schedules November results Qualcomm stock remains near fair value Negative Sentiment: Erste Group cut its fiscal 2027 EPS forecast to $7.28 from $7.31, below the broader consensus estimate of $7.71, indicating modest pressure on forward earnings expectations. Qualcomm earnings estimate cut Negative Sentiment: Qualcomm’s executive vice president sold approximately $437,650 of company stock, which may weigh modestly on sentiment, although a single insider transaction is not necessarily a change in business outlook. Qualcomm insider selling Negative Sentiment: Comparisons with Intel point to Qualcomm’s more uneven revenue trend and recent sequential declines. Reports also describe automotive growth being offset by pressure on handset earnings, keeping smartphone weakness a key risk. Intel versus Qualcomm revenue comparison Qualcomm automotive growth and handset pressure Analysts Set New Price Targets Several brokerages have recently issued reports on QCOM. Robert W. Baird set a $400.00 price target on Qualcomm in a report on Thursday, July 30th. Zacks Research lowered shares of Qualcomm from a “hold” rating to a “strong sell” rating in a research report on Tuesday, September 15th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Qualcomm in a research report on Monday, September 21st. The Goldman Sachs Group set a $160.00 target price on shares of Qualcomm in a research note on Thursday, July 30th. Finally, Morgan Stanley decreased their target price on shares of Qualcomm from $231.00 to $220.00 and set an “equal weight” rating for the company in a research report on Thursday, July 30th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, twenty-one have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $205.83. Read Our Latest Report on QCOM

Qualcomm Price Performance Shares of Qualcomm stock opened at $175.91 on Friday. The company has a current ratio of 2.02, a quick ratio of 1.28 and a debt-to-equity ratio of 0.46. The firm has a fifty day simple moving average of $176.17 and a 200-day simple moving average of $181.00. The stock has a market capitalization of $187.84 billion, a price-to-earnings ratio of 19.55, a PEG ratio of 3.89 and a beta of 1.65. Qualcomm Incorporated has a 1-year low of $121.99 and a 1-year high of $259.92.

Qualcomm (NASDAQ:QCOM – Get Free Report) last posted its earnings results on Wednesday, July 29th. The wireless technology company reported $2.21 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.23 by ($0.02). Qualcomm had a net margin of 21.01% and a return on equity of 38.36%. The firm had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.69 billion. During the same quarter in the previous year, the business posted $2.77 earnings per share. The business’s quarterly revenue was down 4.0% compared to the same quarter last year. Qualcomm has set its Q4 2026 guidance at 2.050-2.250 EPS. On average, sell-side analysts expect that Qualcomm Incorporated will post 7.71 earnings per share for the current year.

Qualcomm Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 17th. Investors of record on Thursday, December 3rd will be given a dividend of $0.92 per share. This represents a $3.68 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Thursday, December 3rd. Qualcomm’s payout ratio is currently 42.59%.

Insider Buying and Selling at Qualcomm In other news, EVP Heather S. Ace sold 3,200 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $147.04, for a total value of $470,528.00. Following the completion of the sale, the executive vice president directly owned 36,535 shares of the company’s stock, valued at approximately $5,372,106.40. This represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Cristiano R. Amon sold 10,000 shares of the stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $200.00, for a total value of $2,000,000.00. Following the completion of the sale, the chief executive officer directly owned 177,568 shares of the company’s stock, valued at $35,513,600. This represents a 5.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 33,458 shares of company stock worth $6,198,144 in the last ninety days. 0.05% of the stock is owned by insiders.

Qualcomm Profile (Free Report)

Qualcomm Incorporated is a technology company that develops and commercializes wireless communications and semiconductor technologies. Through Qualcomm Technologies, Inc, the company designs integrated circuits, system software and related platforms used in smartphones, personal computers, automobiles, industrial equipment, consumer devices and other connected products. Its Snapdragon platforms support mobile computing, connectivity, artificial intelligence and multimedia applications, while its broader portfolio includes radio-frequency systems, networking and edge-computing technologies.

Qualcomm also operates a significant technology-licensing business through its Qualcomm Technology Licensing segment.

Recommended Stories Five stocks we like better than Qualcomm Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for Qualcomm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualcomm and related companies with MarketBeat.com's FREE daily email newsletter.

Moderna Writes Medicine Like SoftwareThis August, Moderna (MRNA -1.25%) and Merck (MRK -1.34%) reported that their personalized cancer vaccine, intismeran autogene, cut the risk of melanoma recurrence after surgery when added to Keytruda. The result came from a phase 3 trial, the large final-stage study regulators lean on for approval. Moderna stock jumped 177% in one day and is up nearly 580% so far this year.

Moderna has plenty more to prove:

The personalized cancer vaccine: Merck and Moderna plan to present the full melanoma data at a medical meeting and to file for FDA approval. They haven’t given a filing date.Other cancers: The same vaccine is being tested in lung, kidney, and bladder cancer. Including melanoma, nine clinical studies are under way.Rare genetic liver disease: Moderna expects pivotal data before year-end in propionic acidemia, an inherited disorder in which the body can’t properly break down certain proteins.Autoimmune disease: This is the next big opportunity that the CEO believes Wall Street hasn’t priced in yet.At FoolFest, our annual member event, Tom Gardner spoke with CEO Stéphane Bancel about the science, the stock reprice, and why he prefers the long-term game over the next quarter.

Key Insights From Moderna’s CEOOn the TechnologyEvery cell in your body runs on messenger RNA, or mRNA. These are short-lived instructions that tell the cell which protein to build. Moderna writes its own instructions. Inject them, and the body builds whatever protein Moderna chose. That could be a piece of a virus for a vaccine, or a cancer marker the immune system can learn to hunt.

What we at Moderna figured out — it took us 10 years to do so before the pandemic — is how to make a safe mRNA molecule in a reactor that will be the instruction for any protein we want your body to make on demand.On Being a Platform CompanyMost drugmakers start from scratch with each new medicine. Moderna’s drugs share the same building blocks and the same factories. Only the code changes.

We knew from the beginning that it was going to be zero drugs or a lot of drugs. It made no scientific sense that it would be a one-drug or a two-drug company.So Moderna established itself as a platform company. Every new approval makes the next medicine easier to develop. So far, the record backs that up. Six of Moderna’s seven phase 3 trials have succeeded. The one miss was a vaccine for CMV, a common virus that can harm babies before birth.

If you look at the industry average, starting from phase 1 to phase 3, it’s around 10%. At Moderna, we’re around 85%.On IntismeranIntismeran is made for one patient at a time. Moderna sequences the patient’s tumor, and an algorithm picks 34 of its mutations. Moderna codes those into a custom vaccine. Patients get it alongside Keytruda, Merck’s blockbuster cancer drug.

Keytruda basically gives energy back to the T cells … that attack your cancer. What intismeran does is, we teach your immune system how to look for new signatures, new mutations in your cancer.After two to three doses, the body generates brand-new T-cells specifically trained to target the tumor. The results have been impressive so far.

From the phase 2 data, at five years out, 80% of people were disease-free, which in skin cancer is considered a cure.On Patents and CompetitionModerna patents the system, layer by layer, rather than one molecule at a time. It keeps filing new patents with every new technology it discovers.

Think about it almost like a lasagna. We build layers and layers and layers of patents on mRNA. And then when you do a drug, you just take a slice of that lasagna.Copycat drugs usually skip costly trials by proving they’re identical to the original. Moderna keeps intismeran’s mutation-picking algorithm secret, even from its CEO, and Bancel doesn’t see how a rival could prove a match without it.

How can you go to the FDA and say it’s the same drug and waive the clinical trial cost? I think this will not happen.On Artificial IntelligenceBancel says AI can tackle highly complex biology and shorten development timelines. After a phase 3 positive study, drugmakers typically spend about six months gathering and cleaning data before they can file for approval. Every month saved is another month of sales.

We are starting more and more to get to three months at Moderna, and I want that to become one day.On the Stock’s 95% DeclineIt was clearly not fun, but we kind of knew this was going to happen … As the sales come down, the market reprices the stock.Bancel is referring to Covid sales here. The company remained undeterred and continued to invest in its platform, which is now paying off. The CEO backed his conviction with his own money.

I had options expiring that were 10 years old … At 29 bucks, I bought all of them, cash. I paid my taxes, I bought everything, I bought 100% of the stock.On the Long-Term GameEarnings per share is the profit figure Wall Street dissects every quarter. Bancel judges Moderna by the cash it returns over 10 years instead.

I’m not looking at the EPS of next quarter. I never have and most probably never will, because what happens next quarter is things we decided and worked on two or three years ago.Today’s Question!Will Moderna beat the market over the next five years? Why, why not?

Discuss with friends and family, or become a member to hear what your fellow Fools are saying!

Atlatl Advisers LLC raised its position in shares of Cisco Systems, Inc. (NASDAQ:CSCO – Free Report) by 477.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 17,445 shares of the network equipment provider’s stock after buying an additional 14,425 shares during the quarter. Atlatl Advisers LLC’s holdings in Cisco Systems were worth $1,878,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Cisco Systems during the second quarter valued at approximately $42,129,647,000. Bank of America Corp DE purchased a new stake in shares of Cisco Systems in the 2nd quarter worth approximately $5,892,379,000. Bank of New York Mellon Corp purchased a new stake in shares of Cisco Systems in the 2nd quarter worth approximately $4,714,574,000. Deutsche Bank AG bought a new position in Cisco Systems during the 2nd quarter valued at approximately $1,997,004,000. Finally, State Street Corp increased its position in Cisco Systems by 7.0% during the 2nd quarter. State Street Corp now owns 207,106,569 shares of the network equipment provider’s stock valued at $25,278,492,000 after buying an additional 13,512,872 shares in the last quarter. 73.33% of the stock is currently owned by institutional investors.

Cisco Systems Trading Up 1.5% Cisco Systems stock opened at $106.50 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 0.93 and a quick ratio of 0.79. Cisco Systems, Inc. has a one year low of $70.06 and a one year high of $130.37. The stock has a market capitalization of $419.89 billion, a PE ratio of 31.89, a price-to-earnings-growth ratio of 2.18 and a beta of 0.99. The business’s fifty day moving average is $110.18 and its 200 day moving average is $109.86.

Cisco Systems (NASDAQ:CSCO – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The network equipment provider reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.17 by $0.05. Cisco Systems had a net margin of 20.95% and a return on equity of 30.16%. The firm had revenue of $17.25 billion for the quarter, compared to the consensus estimate of $16.84 billion. During the same quarter last year, the firm posted $0.99 EPS. The business’s quarterly revenue was up 17.6% compared to the same quarter last year. Cisco Systems has set its FY 2027 guidance at 5.050-5.110 EPS and its Q1 2027 guidance at 1.320-1.340 EPS. On average, sell-side analysts predict that Cisco Systems, Inc. will post 4.42 EPS for the current year. Cisco Systems Announces Dividend The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 21st. Investors of record on Friday, October 2nd were given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date was Friday, October 2nd. Cisco Systems’s dividend payout ratio is 50.30%.

Wall Street Analyst Weigh In Several research firms have commented on CSCO. Rosenblatt Securities boosted their target price on Cisco Systems from $150.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Weiss Ratings reiterated a “buy (b)” rating on shares of Cisco Systems in a research note on Wednesday, August 26th. Piper Sandler dropped their price target on shares of Cisco Systems from $132.00 to $125.00 and set a “neutral” rating on the stock in a research note on Tuesday, September 22nd. Freedom Capital raised shares of Cisco Systems from a “hold” rating to a “strong-buy” rating in a research report on Sunday, August 16th. Finally, HSBC lowered shares of Cisco Systems from a “buy” rating to a “hold” rating and reduced their price objective for the company from $137.00 to $120.00 in a research note on Friday, August 14th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Cisco Systems currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.52.

View Our Latest Stock Report on CSCO

Insider Buying and Selling In other Cisco Systems news, EVP Thimaya Subaiya sold 5,832 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $111.47, for a total value of $650,093.04. Following the transaction, the executive vice president directly owned 128,382 shares of the company’s stock, valued at approximately $14,310,741.54. This trade represents a 4.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Charles Robbins sold 21,628 shares of the company’s stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $111.54, for a total transaction of $2,412,387.12. Following the sale, the chief executive officer directly owned 602,710 shares of the company’s stock, valued at $67,226,273.40. The trade was a 3.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 44,869 shares of company stock valued at $5,005,620 in the last 90 days. Insiders own 0.01% of the company’s stock.

About Cisco Systems (Free Report)

Cisco Systems, Inc is a global technology company that develops networking, cybersecurity, collaboration and observability solutions for businesses, government organizations and service providers. Its offerings include routers, switches, wireless networking equipment, data-center infrastructure, security software and services, as well as technologies that support cloud and hybrid IT environments.

The company also provides collaboration tools through its Webex portfolio, cloud-managed networking through Cisco Meraki and security and observability capabilities that include technologies from Splunk, which Cisco acquired in 2024.

Recommended Stories Five stocks we like better than Cisco Systems Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for Cisco Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cisco Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Fifth Third Wealth Advisors LLC boosted its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 7.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 78,616 shares of the company’s stock after buying an additional 5,418 shares during the period. Fifth Third Wealth Advisors LLC’s holdings in Merck & Co., Inc. were worth $11,424,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares during the last quarter. State Street Corp grew its holdings in shares of Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock worth $15,573,754,000 after buying an additional 1,087,583 shares during the last quarter. Wellington Management Group LLP increased its position in Merck & Co., Inc. by 2.3% in the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after acquiring an additional 1,934,312 shares during the period. Bank of America Corp DE increased its position in Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock valued at $3,701,831,000 after acquiring an additional 2,919,780 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Merck & Co., Inc. by 23.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 15,456,039 shares of the company’s stock valued at $1,858,938,000 after acquiring an additional 2,969,856 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Performance
Shares of MRK opened at $145.25 on Friday. The stock has a market cap of $358.35 billion, a P/E ratio of 116.20, a PEG ratio of 6.83 and a beta of 0.21. The company has a 50-day moving average of $146.98 and a two-hundred day moving average of $130.17. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same period last year, the business posted $2.13 EPS. The company’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts predict that Merck & Co., Inc. will post 2.64 EPS for the current fiscal year.
Merck & Co., Inc. Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were given a dividend of $0.85 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is 272.00%.

Insider Buying and Selling
In other Merck & Co., Inc. news, EVP Richard R. Deluca sold 20,784 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the transaction, the executive vice president directly owned 134,703 shares of the company’s stock, valued at $17,569,312.29. This represents a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total transaction of $10,718,839.90. Following the completion of the transaction, the executive vice president owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last three months. Insiders own 0.17% of the company’s stock.

Analyst Upgrades and Downgrades
A number of analysts have weighed in on MRK shares. Daiwa Securities Group raised Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective for the company in a research report on Wednesday, August 12th. Scotiabank boosted their target price on Merck & Co., Inc. from $155.00 to $180.00 and gave the company a “sector outperform” rating in a report on Tuesday, September 29th. Morgan Stanley cut their price target on Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating for the company in a research note on Wednesday, October 7th. Guggenheim increased their price target on Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday, September 8th. Finally, BMO Capital Markets lifted their price objective on shares of Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, August 20th. Seventeen research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus price target of $151.92.

Check Out Our Latest Research Report on Merck & Co., Inc.

Trending Headlines about Merck & Co., Inc.
Here are the key news stories impacting Merck & Co., Inc. this week:

Positive Sentiment: Merck and Moderna reported positive Phase 3 INTerpath-001 results for the personalized melanoma vaccine, intismeran, combined with Keytruda. The treatment reduced the risk of recurrence or death by 42% and also improved distant metastasis-free survival, supporting the long-term potential of the partnership’s oncology pipeline. Doctors call Moderna and Merck cancer vaccine data a major advancement
Positive Sentiment: The European Commission approved Keytruda plus Padcev as a perioperative treatment for resectable muscle-invasive bladder cancer, regardless of patients’ cisplatin eligibility. The broader label expands the addressable market and represents the EU’s first approval of a PD-1 inhibitor combined with an antibody-drug conjugate in this setting. Merck wins EU approval for Keytruda plus Padcev
Neutral Sentiment: Despite strong clinical results, the vaccine announcement triggered a “sell-the-news” reaction. The data largely met elevated Wall Street expectations after an earlier leak, limiting the immediate upside for MRK even though oncologists viewed the results as an important treatment advance. Merck and Moderna shares fall on cancer vaccine results
Negative Sentiment: Investors remain concerned about valuation and Merck’s future revenue concentration in Keytruda ahead of its patent cliff. Analysts have also characterized the recent rally as leaving limited margin of safety, increasing the risk of profit-taking when news is merely in line with expectations. Merck rally leaves little margin of safety
Negative Sentiment: Erste Group Bank reduced its FY2026 EPS estimate to $2.63 from $2.73 and its FY2027 estimate to $9.38 from $9.47. Separate previews also anticipate a year-over-year decline in quarterly earnings, adding near-term pressure to the shares. Merck earnings preview

Merck & Co., Inc. Company Profile
(Free Report)

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.

See Also

Five stocks we like better than Merck & Co., Inc.
Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

When most people think of Caterpillar (CAT -2.42%), they think of the iconic yellow tractors, harvesters, and other farm equipment that have powered American agriculture for over a century. And of course, the company is also known for its construction equipment, including backhoes, bulldozers, and excavators (also yellow), among many other types of heavy equipment.

But recently, a new narrative has emerged about Caterpillar: It's an artificial intelligence (AI) stock, and one that investors optimistic about the AI revolution should absolutely consider, as a way to diversify away from core AI stocks like Nvidia, Alphabet, and Micron Technology, but still benefit from the massive AI infrastructure build-out now taking place.

How do I know this? Well, just look at the company's most recent quarterly results.

In the second quarter, Caterpillar's total revenue grew an impressive 24% over the same quarter in 2025. And earnings per share soared 73% from a year ago.

Power equipment sales are driving revenue growth
But you only need to dig a little deeper to uncover which segment is really exploding at the company: power generation. Total retail sales for the power and energy segment rose 33% in the quarter. And what drove that? Retail sales of power generation equipment, which climbed an incredible 72%.

In the earnings call after the Q2 results were released on Aug. 4, CEO Joseph Creed said the increase was due to "very strong demand for large gen[erator] sets and turbines used in data center applications."

AI data centers have a nearly insatiable thirst for power, so sales of power-supplying equipment are going gangbusters. In 2025, data centers consumed about 4.9% of the U.S. electricity supply. In some states, that was more than 10%; in data center-heavy Virginia, it's more than one-quarter. Electricity consumption by U.S. data centers is projected to more than double by 2030. And from there, who knows?

Better still, customers for Caterpillar's power and energy equipment are now placing orders through 2030. As a result, the company's backlog, now at a record $72 billion, has expanded 92% over the past year.

$687.00-$17.05 (-2.42%)

NYSE · As of 4:00 PM ET 10/23/26

So, a large portion of Caterpillar's revenue growth right now is driven by data center construction and power needs. And that looks to increase in the coming months and years. Caterpillar calls its power and energy its "Largest and Fastest Growing Segment."

Image source: Getty Images.

Caterpillar will report its third-quarter earnings on Oct. 29. Wall Street expects revenue growth of 17% over the same quarter last year and earnings of $7.03 per share, up 42% from a year ago. I wouldn't be surprised if the company beats those estimates.

For investors who believe, as I do, that the AI spending juggernaut will continue for years to come, investing in Caterpillar is a good way to profit from it while diversifying a bit from the core AI stocks.

Brookstone Capital Management lessened its stake in Linde PLC (NASDAQ:LIN – Free Report) by 12.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 21,466 shares of the basic materials company’s stock after selling 3,074 shares during the period. Brookstone Capital Management’s holdings in Linde were worth $10,189,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. State Street Corp raised its holdings in Linde by 3.7% during the 2nd quarter. State Street Corp now owns 20,344,181 shares of the basic materials company’s stock worth $10,558,016,000 after purchasing an additional 719,052 shares during the last quarter. Amundi increased its position in shares of Linde by 13.4% during the first quarter. Amundi now owns 3,162,409 shares of the basic materials company’s stock worth $1,567,796,000 after buying an additional 373,012 shares during the period. Dimensional Fund Advisors LP raised its stake in Linde by 2.4% during the first quarter. Dimensional Fund Advisors LP now owns 2,740,541 shares of the basic materials company’s stock worth $1,358,712,000 after buying an additional 64,078 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Linde by 28.6% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,624,728 shares of the basic materials company’s stock worth $805,475,000 after buying an additional 361,664 shares during the last quarter. Finally, Swiss National Bank raised its stake in Linde by 6.6% during the first quarter. Swiss National Bank now owns 1,370,361 shares of the basic materials company’s stock worth $679,370,000 after buying an additional 85,360 shares during the last quarter. Institutional investors own 82.80% of the company’s stock.

Wall Street Analysts Forecast Growth Several research firms recently issued reports on LIN. Citigroup dropped their target price on shares of Linde from $580.00 to $560.00 and set a “buy” rating on the stock in a report on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft decreased their price target on Linde from $580.00 to $575.00 and set a “buy” rating for the company in a report on Monday, August 3rd. Weiss Ratings reissued a “buy (b)” rating on shares of Linde in a research report on Monday. DZ Bank reissued a “neutral” rating on shares of Linde in a research note on Thursday, August 6th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Linde in a research report on Thursday, October 8th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $547.10.

View Our Latest Research Report on LIN Linde Trading Down 0.3% NASDAQ LIN opened at $508.83 on Friday. The company has a market cap of $234.56 billion, a price-to-earnings ratio of 32.87, a P/E/G ratio of 2.98 and a beta of 0.71. Linde PLC has a 52 week low of $387.78 and a 52 week high of $548.20. The business has a 50 day moving average price of $480.55 and a 200-day moving average price of $498.37. The company has a quick ratio of 0.75, a current ratio of 0.88 and a debt-to-equity ratio of 0.51.

Linde (NASDAQ:LIN – Get Free Report) last issued its earnings results on Friday, July 31st. The basic materials company reported $4.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.49 by $0.01. Linde had a return on equity of 20.09% and a net margin of 20.43%. The company had revenue of $9.29 billion for the quarter, compared to analysts’ expectations of $9.02 billion. During the same period last year, the business earned $4.09 EPS. Linde’s quarterly revenue was up 9.3% compared to the same quarter last year. Linde has set its FY 2026 guidance at 17.700-17.900 EPS and its Q3 2026 guidance at 4.450-4.550 EPS. As a group, equities analysts expect that Linde PLC will post 17.86 earnings per share for the current fiscal year.

Linde Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Thursday, September 17th. Stockholders of record on Thursday, September 3rd were given a dividend of $1.60 per share. The ex-dividend date of this dividend was Thursday, September 3rd. This represents a $6.40 annualized dividend and a dividend yield of 1.3%. Linde’s payout ratio is presently 41.34%.

Linde Company Profile (Free Report)

Linde plc (NASDAQ:LIN) is a global industrial gases and engineering company. It produces and distributes atmospheric gases such as oxygen, nitrogen and argon, as well as hydrogen, helium, carbon dioxide and specialty gases. The company serves customers through packaged gases, bulk deliveries, on-site production and pipeline systems.

Linde’s products and services support a broad range of industries, including healthcare, food and beverage, manufacturing, chemicals, energy, refining, electronics and metals.

Recommended Stories Five stocks we like better than Linde Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for Linde Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Linde and related companies with MarketBeat.com's FREE daily email newsletter.

Shares of Agnico Eagle Mines Limited (NYSE:AEM – Get Free Report) (TSE:AEM) have been assigned a consensus recommendation of “Moderate Buy” from the nineteen brokerages that are covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $224.33.

Several equities analysts recently weighed in on AEM shares. Barclays increased their price objective on shares of Agnico Eagle Mines from $188.00 to $218.00 and gave the company an “overweight” rating in a report on Monday. Canadian Imperial Bank of Commerce set a $239.00 price objective on shares of Agnico Eagle Mines in a research note on Friday, October 16th. Wall Street Zen lowered shares of Agnico Eagle Mines from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Royal Bank Of Canada upped their target price on shares of Agnico Eagle Mines from $210.00 to $225.00 and gave the company a “sector perform” rating in a research report on Wednesday, September 16th. Finally, RBC Dominion Securities set a $225.00 target price on shares of Agnico Eagle Mines and gave the company a “sector perform” rating in a research report on Thursday.

Get Our Latest Analysis on AEM

More Agnico Eagle Mines News Here are the key news stories impacting Agnico Eagle Mines this week: Positive Sentiment: JPMorgan Chase raised its price target for Agnico Eagle, signaling continued confidence in the company’s outlook. Agnico Eagle Mines Stock Gets Price Target Increase from JPMorgan Chase & Co. Positive Sentiment: Elevated gold prices and reported record cash flow are drawing investor attention because miners generally benefit from widening margins when bullion prices rise. Agnico is also being highlighted as a relatively strong operator with quality assets. Agnico Eagle Mines Draws Focus as Record Cash Flow Meets Elevated Gold Prices Positive Sentiment: RBC Dominion Securities assigned a $225 price target and a “sector perform” rating, while the broader average brokerage recommendation remains favorable. These targets imply substantial upside from recent trading levels, although analyst optimism may be overstated. RBC Dominion Securities price target Neutral Sentiment: Wall Street’s Q3 2026 preview focuses on production, costs, revenue, and other operating metrics. The articles provide estimates rather than actual results, so the upcoming report could become an important catalyst. Agnico Q3 earnings preview Negative Sentiment: Freedom Broker downgraded AEM from “buy” to “hold” and reduced its price target to $212 from $255. The broker cited execution risks at Canadian Malartic and Odyssey, lower earnings and EBITDA projections, cost-inflation concerns, and Agnico’s premium valuation relative to peers. Why Did Agnico Eagle Mines Stock Drop? Negative Sentiment: Erste Group Bank made a small reduction to its FY2027 EPS forecast, lowering it to $12.30 from $12.35. Although modest, the revision reinforces concerns about future earnings growth. Agnico Eagle earnings estimate revision Agnico Eagle Mines Stock Performance Agnico Eagle Mines stock opened at $173.84 on Wednesday. The company has a current ratio of 2.86, a quick ratio of 2.02 and a debt-to-equity ratio of 0.01. Agnico Eagle Mines has a 1 year low of $134.38 and a 1 year high of $255.24. The company has a market cap of $88.13 billion, a PE ratio of 14.87, a PEG ratio of 2.61 and a beta of 0.64. The company’s 50-day moving average is $195.12 and its two-hundred day moving average is $180.99.

Agnico Eagle Mines (NYSE:AEM – Get Free Report) (TSE:AEM) last issued its earnings results on Wednesday, July 29th. The mining company reported $3.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.89 by $0.16. Agnico Eagle Mines had a net margin of 40.44% and a return on equity of 22.04%. The company had revenue of $3.80 billion for the quarter, compared to analyst estimates of $3.78 billion. During the same quarter last year, the firm earned $1.94 EPS. The company’s revenue for the quarter was up 35.0% on a year-over-year basis. Equities analysts anticipate that Agnico Eagle Mines will post 11.45 earnings per share for the current year.

Institutional Investors Weigh In On Agnico Eagle Mines A number of institutional investors have recently made changes to their positions in the stock. Fortitude Family Office LLC lifted its stake in Agnico Eagle Mines by 600.0% in the third quarter. Fortitude Family Office LLC now owns 140 shares of the mining company’s stock valued at $26,000 after buying an additional 120 shares during the period. Markowski Investments bought a new position in Agnico Eagle Mines during the second quarter worth about $29,000. Sawyer & Company Inc bought a new position in Agnico Eagle Mines during the third quarter worth about $35,000. Dunhill Financial LLC bought a new position in Agnico Eagle Mines during the second quarter worth about $31,000. Finally, Fiduciary Financial Advisors acquired a new position in shares of Agnico Eagle Mines during the 2nd quarter worth about $32,000. 68.34% of the stock is owned by institutional investors and hedge funds.

(Get Free Report)

Agnico Eagle Mines Limited (NYSE:AEM) is a Canadian gold mining company engaged in the exploration, development and production of gold, as well as related activities such as mineral processing and mine-site reclamation. The company’s principal product is gold, with silver and other byproducts also recovered from certain operations.

Founded in 1957 through the merger of Agnico Mines and Eagle Mines, Agnico Eagle has grown into one of the world’s largest gold producers. Its operating portfolio is concentrated in established mining regions, including the Canadian provinces of Ontario and Quebec, Nunavut in northern Canada, and Finland.

Further Reading Five stocks we like better than Agnico Eagle Mines Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for Agnico Eagle Mines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agnico Eagle Mines and related companies with MarketBeat.com's FREE daily email newsletter.

Axxcess Wealth Management LLC cut its holdings in shares of MetLife, Inc. (NYSE:MET – Free Report) by 46.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 15,011 shares of the financial services provider’s stock after selling 13,162 shares during the period. Axxcess Wealth Management LLC’s holdings in MetLife were worth $1,413,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of MET. Nykredit A S bought a new stake in shares of MetLife in the 2nd quarter valued at about $178,638,000. Two Sigma Securities LLC acquired a new stake in shares of MetLife in the 2nd quarter valued at approximately $4,204,000. NewEdge Advisors LLC raised its position in shares of MetLife by 20.1% in the 2nd quarter. NewEdge Advisors LLC now owns 74,002 shares of the financial services provider’s stock valued at $6,261,000 after acquiring an additional 12,378 shares during the period. OMERS ADMINISTRATION Corp bought a new position in MetLife during the 2nd quarter worth approximately $2,683,000. Finally, Bank of Nova Scotia bought a new position in MetLife during the 2nd quarter worth approximately $14,182,000. Institutional investors own 94.99% of the company’s stock.

Wall Street Analyst Weigh In Several equities research analysts have commented on MET shares. Mizuho lowered their target price on shares of MetLife from $112.00 to $109.00 and set an “outperform” rating for the company in a research note on Wednesday, October 7th. Morgan Stanley lifted their price target on shares of MetLife from $103.00 to $111.00 and gave the stock an “overweight” rating in a research report on Monday, August 24th. JPMorgan Chase & Co. upped their price objective on shares of MetLife from $108.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, October 15th. UBS Group upped their price objective on shares of MetLife from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Tuesday, October 6th. Finally, TD Cowen raised their price objective on MetLife from $110.00 to $114.00 and gave the stock a “buy” rating in a research note on Wednesday. Thirteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, MetLife presently has an average rating of “Moderate Buy” and an average target price of $105.44.

View Our Latest Analysis on MET MetLife Trading Down 4.5% NYSE MET opened at $98.86 on Friday. The company has a market cap of $63.61 billion, a PE ratio of 18.94, a PEG ratio of 0.98 and a beta of 0.78. The company has a current ratio of 0.20, a quick ratio of 0.20 and a debt-to-equity ratio of 0.52. MetLife, Inc. has a 12 month low of $67.33 and a 12 month high of $103.65. The stock has a 50 day moving average of $97.27 and a 200-day moving average of $89.81.

MetLife (NYSE:MET – Get Free Report) last issued its earnings results on Wednesday, August 5th. The financial services provider reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.13. The business had revenue of $13.52 billion for the quarter, compared to the consensus estimate of $19.67 billion. MetLife had a net margin of 4.57% and a return on equity of 23.39%. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the previous year, the company earned $2.02 earnings per share. On average, equities research analysts anticipate that MetLife, Inc. will post 9.94 EPS for the current fiscal year.

MetLife announced that its board has initiated a stock repurchase plan on Wednesday, August 5th that allows the company to buy back $3.00 billion in outstanding shares. This repurchase authorization allows the financial services provider to purchase up to 4.8% of its shares through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

MetLife Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 3rd will be issued a dividend of $0.5925 per share. The ex-dividend date is Tuesday, November 3rd. This represents a $2.37 dividend on an annualized basis and a yield of 2.4%. MetLife’s dividend payout ratio (DPR) is presently 45.40%.

MetLife Profile (Free Report)

MetLife, Inc (NYSE: MET) is a global financial services company that provides insurance, retirement, and employee benefits solutions to individuals, employers, and institutions. Its offerings include life insurance, dental and vision coverage, accident and disability insurance, annuities, retirement savings products, and related financial services.

Through its institutional and workplace businesses, MetLife helps employers provide benefits and retirement programs to their employees. The company also serves individual customers with protection and income products.

Featured Articles Five stocks we like better than MetLife Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for MetLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetLife and related companies with MarketBeat.com's FREE daily email newsletter.

Crossmark Global Holdings Inc. decreased its holdings in Simon Property Group, Inc. (NYSE:SPG – Free Report) by 20.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,242 shares of the real estate investment trust’s stock after selling 6,057 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Simon Property Group were worth $4,666,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in SPG. Ancora Advisors LLC bought a new stake in Simon Property Group during the 2nd quarter valued at approximately $27,000. Osbon Capital Management LLC purchased a new position in shares of Simon Property Group during the 2nd quarter worth approximately $32,000. Fiduciary Financial Advisors bought a new position in shares of Simon Property Group in the 2nd quarter worth approximately $34,000. Dynamic Wealth Strategies LLC raised its position in shares of Simon Property Group by 195.8% in the 1st quarter. Dynamic Wealth Strategies LLC now owns 210 shares of the real estate investment trust’s stock worth $39,000 after acquiring an additional 139 shares in the last quarter. Finally, N.E.W. Advisory Services LLC raised its position in shares of Simon Property Group by 335.0% in the 2nd quarter. N.E.W. Advisory Services LLC now owns 174 shares of the real estate investment trust’s stock worth $39,000 after acquiring an additional 134 shares in the last quarter. Institutional investors own 93.01% of the company’s stock.

Simon Property Group Stock Down 0.1%
SPG opened at $211.85 on Friday. The firm’s 50 day simple moving average is $207.72 and its two-hundred day simple moving average is $211.24. The company has a market capitalization of $68.54 billion, a PE ratio of 14.94, a PEG ratio of 3.27 and a beta of 1.30. Simon Property Group, Inc. has a 1-year low of $172.19 and a 1-year high of $238.50. The company has a current ratio of 1.05, a quick ratio of 1.05 and a debt-to-equity ratio of 5.19.

Simon Property Group (NYSE:SPG – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The real estate investment trust reported $1.49 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.15). The business had revenue of $1.79 billion for the quarter, compared to the consensus estimate of $1.61 billion. Simon Property Group had a net margin of 66.56% and a return on equity of 89.32%. The company’s revenue was up 19.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.70 EPS. Simon Property Group has set its FY 2026 guidance at 13.200-13.300 EPS. As a group, equities analysts forecast that Simon Property Group, Inc. will post 13.24 EPS for the current year.
Simon Property Group Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 4.2%. The ex-dividend date was Wednesday, September 9th. Simon Property Group’s dividend payout ratio (DPR) is presently 63.47%.

Insider Activity
In other Simon Property Group news, Director Reuben Leibowitz purchased 480 shares of the business’s stock in a transaction on Wednesday, September 30th. The stock was acquired at an average price of $202.78 per share, for a total transaction of $97,334.40. Following the purchase, the director owned 56,277 shares of the company’s stock, valued at approximately $11,411,850.06. This represents a 0.86% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Stefan Selig purchased 208 shares of the business’s stock in a transaction on Wednesday, September 30th. The stock was acquired at an average price of $202.78 per share, with a total value of $42,178.24. Following the purchase, the director directly owned 34,020 shares in the company, valued at $6,898,575.60. This represents a 0.62% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders purchased 1,668 shares of company stock worth $338,237. 8.73% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In
SPG has been the subject of a number of research analyst reports. Piper Sandler lowered their target price on Simon Property Group from $285.00 to $254.00 and set an “overweight” rating for the company in a research note on Monday, October 12th. Citigroup upped their price target on Simon Property Group from $205.00 to $230.00 and gave the stock a “neutral” rating in a research note on Monday, August 17th. Mizuho increased their price objective on Simon Property Group from $211.00 to $226.00 and gave the stock a “neutral” rating in a report on Thursday, August 27th. Deutsche Bank Aktiengesellschaft lowered Simon Property Group from a “buy” rating to a “hold” rating and set a $220.00 price objective for the company. in a research report on Thursday, July 9th. Finally, Bank of America boosted their target price on shares of Simon Property Group from $225.00 to $236.00 and gave the company a “buy” rating in a report on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat.com, Simon Property Group presently has a consensus rating of “Hold” and a consensus price target of $224.07.

Get Our Latest Stock Report on Simon Property Group

(Free Report)

Simon Property Group, Inc is a self-administered and self-managed real estate investment trust that owns, develops, and operates premier shopping, dining, entertainment, and mixed-use destinations. Its portfolio includes regional malls, premium outlet centers, and other retail properties designed to serve both local shoppers and visitors.

The company’s properties feature a broad mix of retailers, restaurants, entertainment venues, and experiential offerings. Simon also provides property management, leasing, development, redevelopment, and marketing services associated with its real estate portfolio.

Simon Property Group was formed in 1993 through the combination of the retail real estate interests of the Simon and DeBartolo families.

Featured Articles

Five stocks we like better than Simon Property Group
Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for Simon Property Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simon Property Group and related companies with MarketBeat.com's FREE daily email newsletter.

Palantir's 93% revenue growth and 62% adjusted operating margin demonstrate exceptional software economics. U.S. commercial revenue surged 149%, while expanding customer relationships suggest AI adoption is far from slowing down. Palantir's $4.9 billion contracted backlog provides valuable insight into its future revenue growth.

Brookstone Capital Management boosted its holdings in shares of Micron Technology, Inc. (NASDAQ:MU – Free Report) by 51.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,878 shares of the semiconductor manufacturer’s stock after acquiring an additional 20,369 shares during the period. Micron Technology accounts for about 0.6% of Brookstone Capital Management’s investment portfolio, making the stock its 29th largest holding. Brookstone Capital Management’s holdings in Micron Technology were worth $63,777,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. SeaCrest Wealth Management LLC raised its position in shares of Micron Technology by 23.0% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 7,939 shares of the semiconductor manufacturer’s stock valued at $8,456,000 after purchasing an additional 1,482 shares during the period. Virtue Asset Management LLC lifted its position in Micron Technology by 2.3% during the 3rd quarter. Virtue Asset Management LLC now owns 1,115 shares of the semiconductor manufacturer’s stock worth $1,187,000 after acquiring an additional 25 shares during the period. Legacy Financial Group Inc. raised its holdings in shares of Micron Technology by 62.5% during the third quarter. Legacy Financial Group Inc. now owns 580 shares of the semiconductor manufacturer’s stock worth $618,000 after purchasing an additional 223 shares during the last quarter. NBT Bank N.A. acquired a new position in shares of Micron Technology in the third quarter worth about $241,000. Finally, Root Financial Partners LLC raised its position in shares of Micron Technology by 8.7% during the 3rd quarter. Root Financial Partners LLC now owns 4,257 shares of the semiconductor manufacturer’s stock worth $4,534,000 after purchasing an additional 339 shares during the last quarter. 80.84% of the stock is owned by hedge funds and other institutional investors.

Micron Technology Stock Performance MU opened at $877.55 on Friday. Micron Technology, Inc. has a 12-month low of $192.59 and a 12-month high of $1,255.00. The company has a quick ratio of 2.94, a current ratio of 3.31 and a debt-to-equity ratio of 0.03. The business has a 50 day moving average of $983.61 and a 200-day moving average of $880.05. The stock has a market cap of $992.88 billion, a price-to-earnings ratio of 11.83, a PEG ratio of 0.15 and a beta of 2.22.

Micron Technology (NASDAQ:MU – Get Free Report) last announced its earnings results on Wednesday, September 30th. The semiconductor manufacturer reported $33.42 EPS for the quarter, topping the consensus estimate of $31.77 by $1.65. The company had revenue of $54.23 billion for the quarter, compared to analysts’ expectations of $51.33 billion. Micron Technology had a net margin of 63.80% and a return on equity of 92.62%. The business’s revenue for the quarter was up 379.1% on a year-over-year basis. During the same period last year, the firm earned $3.03 earnings per share. Micron Technology has set its Q1 2027 guidance at 37.150-39.150 EPS. On average, equities research analysts expect that Micron Technology, Inc. will post 177.03 earnings per share for the current year. Micron Technology Dividend Announcement The business also recently declared a quarterly dividend, which will be paid on Thursday, October 29th. Stockholders of record on Wednesday, October 14th will be paid a $0.15 dividend. The ex-dividend date of this dividend is Wednesday, October 14th. This represents a $0.60 annualized dividend and a dividend yield of 0.1%. Micron Technology’s dividend payout ratio is presently 0.81%.

Insider Activity at Micron Technology In other news, CEO Sanjay Mehrotra sold 40,000 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $968.90, for a total transaction of $38,756,000.00. Following the transaction, the chief executive officer owned 264,503 shares in the company, valued at approximately $256,276,956.70. This represents a 13.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott J. Deboer sold 28,545 shares of the stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $900.00, for a total value of $25,690,500.00. Following the completion of the sale, the insider directly owned 147,430 shares of the company’s stock, valued at approximately $132,687,000. This trade represents a 16.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 83,545 shares of company stock worth $78,460,850 over the last quarter. Company insiders own 0.24% of the company’s stock.

Analysts Set New Price Targets A number of brokerages have issued reports on MU. Zacks Research upgraded shares of Micron Technology from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 6th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $2,000.00 price target on shares of Micron Technology in a report on Thursday, October 1st. UBS Group reiterated a “buy” rating and issued a $1,625.00 price objective (up from $535.00) on shares of Micron Technology in a report on Wednesday, September 23rd. Robert W. Baird upped their target price on Micron Technology from $1,280.00 to $1,520.00 and gave the stock an “outperform” rating in a research report on Monday, September 28th. Finally, ThinkEquity restated a “buy” rating on shares of Micron Technology in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, forty-one have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Micron Technology currently has a consensus rating of “Moderate Buy” and an average target price of $1,407.88.

Read Our Latest Stock Analysis on MU

More Micron Technology News Here are the key news stories impacting Micron Technology this week:

Positive Sentiment: Improved industry sentiment: A broad rebound in semiconductor stocks lifted Micron, SK Hynix and SanDisk as investors returned to AI and memory names following a sharp pullback. Why are Micron, SK Hynix, and SanDisk stocks climbing on Friday? Positive Sentiment: Favorable supply dynamics: SK Hynix’s decision to abandon a planned U.S. IPO for its Solidigm flash-memory unit could reduce concerns about additional NAND supply entering the market, potentially benefiting Micron and SanDisk. Micron, Sandisk gain as SK Hynix scraps Solidigm IPO Positive Sentiment: Analyst and growth support: Erste Group raised its FY2028 EPS forecast to $201.26 from $199.05 and maintained a Buy rating. Analysts continue to point to Micron’s AI-driven HBM demand, improving margins and relatively low valuation as reasons for optimism. Micron earnings estimate update Neutral Sentiment: Strategic investment: Micron’s planned investment in U.S. critical-mineral processing supports its domestic supply-chain strategy, although the near-term financial impact is unclear. Micron critical-minerals investment Negative Sentiment: Technology execution risk: Micron’s next-generation memory architecture could improve data movement for AI processors, but placing more memory closer to computing units creates difficult cooling and heat-management challenges. Micron’s Next AI Memory Breakthrough Has a Cooling Problem Negative Sentiment: Insider selling and volatility: Recent filings show extensive insider selling with no reported open-market purchases, while technical commentary warns that the recovery remains fragile amid ongoing concerns about AI spending, interest rates and valuation. Micron Technology Company Profile (Free Report)

Micron Technology, Inc is a semiconductor company that develops and manufactures memory and storage products. Its portfolio includes dynamic random-access memory (DRAM), NAND flash memory, NOR flash memory, solid-state drives, memory modules, and other semiconductor solutions used in data centers, personal computers, smartphones, automotive systems, industrial equipment, and consumer electronics.

The company also provides high-bandwidth memory and other advanced memory technologies designed to support artificial intelligence, high-performance computing, networking, and graphics applications.

See Also Five stocks we like better than Micron Technology Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat Want to see what other hedge funds are holding MU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Micron Technology, Inc. (NASDAQ:MU – Free Report).

Receive News & Ratings for Micron Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Micron Technology and related companies with MarketBeat.com's FREE daily email newsletter.

The artificial intelligence (AI) investing thesis has been tough during the past month, but a bundle of tech earnings can change sentiment. Alphabet (GOOG -1.08%) (GOOGL -1.24%), Microsoft (MSFT +0.66%), and Amazon (AMZN -0.95%) are some of the tech giants slated to report earnings by the end of the month, and these are the key details every investor should monitor.

Image source: Getty Images.

AI capital expenditures
If hyperscalers say that they will continue to ramp up spending, it gives chipmakers, neoclouds, and other companies at the center of the AI trade full permission to rebound.

Elon Musk offered some good news when SpaceX (SPCX +1.89%) reported earnings earlier this month. He told investors that hyperscalers and AI enterprises have been relentlessly "hound[ing]" SpaceX for more compute. Even SpaceX is struggling to find compute, with Musk expecting the superintelligence computing capacity shortage to last for years.

That backdrop suggests hyperscalers will spend more than expected and project even higher AI capital expenditures into the fourth quarter and beyond.

That would be good news, but it's equally important to assess how each company will fund its capital expenditures. Microsoft already told investors it would achieve positive free cash flow in its fiscal 2027, suggesting that the AI build-out is sustainable.

Revenue growth rates
All this spending has to translate into positive returns to justify the huge cost of the AI build-out. That's why investors should closely look at year-over-year growth rates for the tech giants. It's already clear that chipmakers are still doing well. Micron (MU +2.46%) posted 379% year-over-year revenue growth in its fiscal Q4 2026 as demand for its memory chips continues to soar.

However, all those chips have to translate into meaningful revenue growth rates for hyperscalers to justify the increased capital expenditures. Alphabet's cloud revenue, specifically, will be on my radar. That part of the business has been accelerating a lot lately, including an 82% year-over-year growth rate in the second quarter. The more Google Cloud's revenue growth rate accelerates in the third quarter, the better it is for the AI trade.

GOOGL Alphabet$320.21-$4.01 (-1.24%)

NASDAQ · As of 4:00 PM ET 10/23/26

Profitability also matters, but there are two reasons I am not looking at net income as much. First, it's normal for tech innovations to be unprofitable for multiple years before enjoying dramatic profit margin expansion upon profitability. Google Cloud is a great example, since it was unprofitable for more than a decade.

Second, net income has been murky for some tech giants due to their large investments in SpaceX and Anthropic. Returns from those investments influence net income, but don't indicate how well the underlying businesses are actually doing. For this earnings cycle, operating income is a more reliable metric than net income, because the former isn't affected by large investments that are performing well for now.

Forward guidance
Chipmakers have offered forward guidance that implies demand will continue. The projections from tech giants will suggest how they feel about current AI expenditures, and whether it is translating into higher growth rates.

Commentary from tech leaders will also reveal where they see AI heading. For instance, Amazon Chief Executive Officer Andy Jassy told investors that Amazon Web Services was booming in Q2, and that "there's a lot to be excited about."

One of the downsides was that Amazon reported a cash outflow of $7.6 billion for the trailing 12 months, mainly due to AI investments. That's a big drop from the $18.2 billion in positive free cash flow for the trailing 12 months ended June 30, 2025.

Any hints at positive free cash flow, like the one Microsoft provided at the conclusion of its fiscal 2026, will bode well for AI stocks.

It's no secret that many people are using AI models, and various businesses have enhanced their products and services thanks to AI. Wall Street's biggest concern is the financial viability of it all, and encouraging management projections may be what investors need to start another stock market rally.

Credit Capital Investments LLC purchased a new stake in Occidental Petroleum Corporation (NYSE:OXY – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 8,000 shares of the oil and gas producer’s stock, valued at approximately $443,000. Occidental Petroleum makes up 0.2% of Credit Capital Investments LLC’s holdings, making the stock its 27th largest position.

A number of other institutional investors have also recently modified their holdings of the stock. Axiom Investment Management LLC acquired a new stake in shares of Occidental Petroleum in the 1st quarter valued at $25,000. Hara Capital LLC bought a new stake in Occidental Petroleum during the 2nd quarter valued at $25,000. GKV Capital Management Co. Inc. purchased a new position in Occidental Petroleum during the 1st quarter worth $26,000. Portus Wealth Advisors LLC bought a new stake in shares of Occidental Petroleum during the 1st quarter worth $29,000. Finally, Fiduciary Financial Advisors purchased a new stake in Occidental Petroleum in the 2nd quarter worth about $31,000. 88.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes Several equities analysts have recently weighed in on the company. BMO Capital Markets reiterated a “market perform” rating and issued a $68.00 price target on shares of Occidental Petroleum in a research report on Wednesday, October 14th. Wells Fargo & Company raised their price objective on Occidental Petroleum from $79.00 to $82.00 and gave the company an “overweight” rating in a report on Monday, September 14th. Seaport Research Partners assumed coverage on Occidental Petroleum in a research note on Thursday, September 3rd. They issued a “buy” rating and a $73.00 target price for the company. Truist Financial upped their price objective on shares of Occidental Petroleum from $63.00 to $64.00 and gave the company a “hold” rating in a research note on Thursday, October 15th. Finally, Wall Street Zen raised shares of Occidental Petroleum from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 10th. Thirteen analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $67.46.

View Our Latest Stock Analysis on OXY Occidental Petroleum Price Performance NYSE:OXY opened at $64.18 on Friday. The company has a current ratio of 1.41, a quick ratio of 1.13 and a debt-to-equity ratio of 0.40. Occidental Petroleum Corporation has a 12 month low of $38.80 and a 12 month high of $67.45. The company has a market capitalization of $64.15 billion, a P/E ratio of 14.17, a P/E/G ratio of 0.73 and a beta of 0.24. The business’s 50-day moving average is $59.86 and its 200 day moving average is $57.25.

Occidental Petroleum (NYSE:OXY – Get Free Report) last posted its earnings results on Wednesday, August 5th. The oil and gas producer reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of $1.83 by $0.57. Occidental Petroleum had a net margin of 28.36% and a return on equity of 15.31%. The business had revenue of $8.06 billion for the quarter, compared to the consensus estimate of $7.07 billion. During the same quarter last year, the firm posted $0.39 EPS. The company’s revenue for the quarter was up 53.4% on a year-over-year basis. On average, equities research analysts forecast that Occidental Petroleum Corporation will post 6.72 earnings per share for the current fiscal year.

Occidental Petroleum Increases Dividend The firm also recently announced a quarterly dividend, which was paid on Thursday, October 15th. Investors of record on Thursday, September 10th were paid a dividend of $0.28 per share. The ex-dividend date was Thursday, September 10th. This is a positive change from Occidental Petroleum’s previous quarterly dividend of $0.26. This represents a $1.12 annualized dividend and a yield of 1.7%. Occidental Petroleum’s dividend payout ratio (DPR) is presently 17.34%.

Occidental Petroleum Profile (Free Report)

Occidental Petroleum Corporation is an energy company engaged in oil and natural gas exploration, development and production. Its operations are focused primarily on the United States, including the Permian and DJ basins, as well as selected international regions in the Middle East and North Africa.

The company’s OxyChem subsidiary manufactures and markets chlor-alkali chemicals, vinyls and other chemical products used in water treatment, construction, healthcare, packaging and industrial applications.

Recommended Stories Five stocks we like better than Occidental Petroleum Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat Want to see what other hedge funds are holding OXY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Occidental Petroleum Corporation (NYSE:OXY – Free Report).

Receive News & Ratings for Occidental Petroleum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Occidental Petroleum and related companies with MarketBeat.com's FREE daily email newsletter.

State Street SPDR Portfolio Developed World ex-US ETF (SPDW -0.30%) targets established international economies with extremely low fees, while iShares Core MSCI Emerging Markets ETF (IEMG +0.40%) provides exposure to higher-growth developing nations.

Investors seeking international diversification must often decide between established developed markets and faster-growing emerging economies. While both the State Street and iShares funds provide broad exposure outside the United States, they target different geographic regions and risk profiles. This comparison examines how their costs, yields, and underlying holdings differ.

Snapshot (cost & size)MetricIEMGSPDWIssueriSharesSPDRShare price$78.09 (as of 2026-10-15)$49.52 (as of 2026-10-15)Expense ratio0.09%0.03%1-yr return (as of Oct. 15, 2026)20.3%18.5%Dividend yield2.4%3.1%Beta0.760.86AUM$154.5 billion$40.8 billionBeta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.

The State Street fund is significantly more affordable, with an expense ratio of 0.03% that undercuts the 0.09% fee charged by the iShares ETF. It also offers a more significant income stream, with a trailing yield 0.84 percentage points higher.

Performance & risk comparisonMetricIEMGSPDWMax drawdown (5 yr)(32.7%)(29.8%)Growth of $1,000 over 5 years (total return)$1,417$1,557What's insideState Street SPDR Portfolio Developed World ex-US ETF focuses on major economies like Japan, the United Kingdom, and Canada. Its portfolio is concentrated in financial services (25%), industrials (18%), and technology (15%). The fund holds 2,417 stocks, and its largest positions include Samsung Electronics (KOSE:A005930)) at 2.32%, ASML Holding (ASML +0.72%) at 1.95%, and SK Hynix (SKHY +4.05%) at 1.72%. It was launched in 2007. State Street SPDR Portfolio Developed World ex-US ETF has paid $1.52 per share over the trailing 12 months, which on its recent ~$49.52 share price works out to a 3.1% yield.

The iShares Core MSCI Emerging Markets ETF provides a different flavor of international exposure by tracking 2,801 companies in developing nations like China, India, and Brazil. It leans significantly more into technology at 42%, followed by financial services at 21% and consumer cyclicals at 8%. Top holdings include Taiwan Semiconductor Manufacturing (TSM +1.49%) at 13.99%, Samsung Electronics at 5.94%, and SK Hynix at 4.06%. It was launched in 2012. iShares Core MSCI Emerging Markets ETF has paid $1.80 per share over the trailing 12 months, which on its recent ~$78.09 share price works out to a 2.2% yield.

For more guidance on ETF investing, check out the full guide at this link.

Which looks like the better buyBoth funds offer compelling opportunities outside the U.S., but for long-term investors, the State Street SPDR Portfolio Developed World ex-US ETF looks like the better buy.

The iShares Core MSCI Emerging Markets ETF is certainly attractive given its substantial exposure to the semiconductor industry. Companies like Taiwan Semiconductor Manufacturing, Samsung Electronics, and SK Hynix are central to the global AI infrastructure buildout, providing investors with exposure to one of the most significant growth trends in today's market.

However, that opportunity comes with additional risks. Emerging markets remain sensitive to currency fluctuations, geopolitical uncertainty, and shifts in global investor sentiment. With roughly 42% of its portfolio concentrated in technology, the fund is also heavily dependent on the industry's continued strength.

Meanwhile, the State Street fund offers a considerably lower expense ratio of just 0.03%, a higher dividend yield, and exposure to established international economies. It also maintains holdings in semiconductor leaders, allowing investors to participate in the AI boom without concentrating so heavily on technology.

For investors looking to build a diversified international portfolio, State Street's ETF looks better positioned. The iShares fund may deliver greater upside, but the State Street SPDR Portfolio Developed World ex-US ETF offers a more balanced combination of income, cost efficiency, and long-term growth potential.

Crossmark Global Holdings Inc. increased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 5.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 46,657 shares of the company’s stock after purchasing an additional 2,507 shares during the period. Eli Lilly and Company makes up 0.7% of Crossmark Global Holdings Inc.’s holdings, making the stock its 25th biggest holding. Crossmark Global Holdings Inc.’s holdings in Eli Lilly and Company were worth $53,986,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Maseco LLP increased its stake in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares during the last quarter. Marshall & Sterling Wealth Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after purchasing an additional 15 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth $42,000. Caitlin John LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $64,000. Finally, IMG Wealth Management Inc. boosted its stake in Eli Lilly and Company by 500.0% in the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock valued at $72,000 after buying an additional 50 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Manufacturing expansion supports long-term growth. Lilly broke ground on a $5 billion facility in Goochland County, Virginia, its first U.S. site designed to produce both active pharmaceutical ingredients and finished medicines. The project is part of a more than $50 billion U.S. manufacturing expansion and is expected to create 650 jobs, improving supply capacity for next-generation cancer and other complex medicines. Lilly Richmond manufacturing facility announcement Positive Sentiment: Weight-loss drug demand remains a major growth driver. Analysts expect emerging-market sales of weight-loss drugs to become a significant opportunity, supporting the long-term outlook for Mounjaro, Zepbound and related incretin products. Lilly’s recent growth has been driven by increasing volume, even as pricing has declined. JP Morgan emerging-market weight-loss drug outlook Positive Sentiment: Some analysts are raising earnings expectations. Erste Group Bank increased its FY2027 EPS forecast for Lilly to $47.77 from $47.30, signaling confidence in the company’s longer-term earnings trajectory. Erste Group Bank EPS estimate update Neutral Sentiment: ESG progress may support the company’s reputation but is unlikely to drive near-term trading. Lilly was cited for combining philanthropy with environmental initiatives while maintaining rapid commercial growth. Eli Lilly sustainability leadership article Negative Sentiment: Near-term earnings risk is weighing on sentiment. Previews anticipate a decline in third-quarter earnings, raising concerns that the stock’s elevated valuation leaves limited room for disappointment ahead of the upcoming report. Lilly Q3 earnings preview Negative Sentiment: Institutional trimming adds selling pressure. Polen Capital reduced its position in Lilly during the third quarter, although it reportedly maintained confidence in the company’s outlook. Polen Capital trims Lilly position Analyst Ratings Changes A number of research analysts have issued reports on the company. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 15th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $1,500.00 price target on shares of Eli Lilly and Company in a research note on Monday, October 12th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. The Goldman Sachs Group restated a “buy” rating and set a $1,413.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday. Finally, TD Cowen reaffirmed a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,317.93. Get Our Latest Stock Report on Eli Lilly and Company

LLY stock opened at $1,275.50 on Friday. The stock’s 50 day simple moving average is $1,186.64 and its 200 day simple moving average is $1,120.24. The company has a market cap of $1.20 trillion, a P/E ratio of 42.80, a price-to-earnings-growth ratio of 1.74 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $809.63 and a fifty-two week high of $1,321.21.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the firm posted $6.31 earnings per share. The firm’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts expect that Eli Lilly and Company will post 33.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile (Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.

Featured Articles Five stocks we like better than Eli Lilly and Company Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Halter Ferguson Financial Inc. trimmed its position in Eli Lilly and Company (NYSE: LLY) by 90.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 814 shares of the company's stock after selling 7,473 shares during the

Brookstone Capital Management reduced its stake in shares of Lockheed Martin Corporation (NYSE:LMT – Free Report) by 4.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,082 shares of the aerospace company’s stock after selling 852 shares during the quarter. Brookstone Capital Management’s holdings in Lockheed Martin were worth $10,227,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of LMT. SeaCrest Wealth Management LLC boosted its stake in Lockheed Martin by 2.9% in the third quarter. SeaCrest Wealth Management LLC now owns 1,621 shares of the aerospace company’s stock valued at $825,000 after acquiring an additional 46 shares during the last quarter. NBT Bank N.A. bought a new stake in shares of Lockheed Martin during the 3rd quarter valued at $4,194,000. Isthmus Partners LLC raised its position in shares of Lockheed Martin by 0.6% during the 3rd quarter. Isthmus Partners LLC now owns 24,384 shares of the aerospace company’s stock valued at $12,418,000 after acquiring an additional 138 shares during the last quarter. Precedent Wealth Partners LLC lifted its stake in shares of Lockheed Martin by 19.3% in the 3rd quarter. Precedent Wealth Partners LLC now owns 5,673 shares of the aerospace company’s stock valued at $2,889,000 after purchasing an additional 919 shares during the period. Finally, Smith Chas P & Associates PA Cpas lifted its stake in shares of Lockheed Martin by 0.8% in the 3rd quarter. Smith Chas P & Associates PA Cpas now owns 88,708 shares of the aerospace company’s stock valued at $48,975,000 after purchasing an additional 668 shares during the period. Institutional investors and hedge funds own 74.19% of the company’s stock.

Lockheed Martin Stock Performance Shares of LMT opened at $604.87 on Friday. The company has a debt-to-equity ratio of 2.04, a quick ratio of 1.01 and a current ratio of 1.26. Lockheed Martin Corporation has a twelve month low of $437.25 and a twelve month high of $692.00. The firm’s 50 day moving average price is $538.52 and its two-hundred day moving average price is $542.30. The firm has a market cap of $139.60 billion, a P/E ratio of 21.49, a PEG ratio of 1.27 and a beta of 0.09.

Lockheed Martin (NYSE:LMT – Get Free Report) last announced its earnings results on Thursday, October 22nd. The aerospace company reported $7.97 earnings per share for the quarter, topping analysts’ consensus estimates of $7.52 by $0.45. The firm had revenue of $20.71 billion during the quarter, compared to analyst estimates of $20.48 billion. Lockheed Martin had a net margin of 8.23% and a return on equity of 83.41%. The company’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same period in the prior year, the business earned $6.95 EPS. On average, analysts forecast that Lockheed Martin Corporation will post 30.49 EPS for the current fiscal year. Lockheed Martin Increases Dividend The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Tuesday, December 1st will be paid a dividend of $3.60 per share. The ex-dividend date of this dividend is Tuesday, December 1st. This represents a $14.40 annualized dividend and a dividend yield of 2.4%. This is an increase from Lockheed Martin’s previous quarterly dividend of $3.45. Lockheed Martin’s dividend payout ratio (DPR) is 51.15%.

Wall Street Analysts Forecast Growth Several research analysts have recently issued reports on LMT shares. Wall Street Zen lowered Lockheed Martin from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 17th. Vertical Research upgraded Lockheed Martin from a “hold” rating to a “buy” rating and set a $600.00 price objective for the company in a report on Wednesday, October 14th. Morgan Stanley increased their target price on Lockheed Martin from $653.00 to $690.00 and gave the company an “equal weight” rating in a research note on Friday, July 24th. Jefferies Financial Group restated a “hold” rating on shares of Lockheed Martin in a report on Wednesday, September 2nd. Finally, Citigroup boosted their target price on Lockheed Martin from $691.00 to $706.00 and gave the stock a “buy” rating in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $632.33.

Get Our Latest Stock Report on Lockheed Martin

Lockheed Martin News Summary Here are the key news stories impacting Lockheed Martin this week:

Positive Sentiment: Q3 beat and raised outlook: Lockheed reported adjusted EPS of $7.97 versus the $7.52 consensus, while revenue rose 11.3% year over year to $20.71 billion. Management now expects 2026 sales of $80 billion-$82 billion and EPS of $30.35-$30.75. Lockheed Martin Reports Third Quarter 2026 Financial Results Positive Sentiment: Record backlog supports future revenue: Total backlog reached approximately $292 billion, up sharply from the prior quarter, with much of the increase coming from PAC-3 and THAAD missile-defense orders. Missiles and Fire Control sales grew 24% as production accelerated, strengthening visibility into long-term growth. Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Positive Sentiment: Long-term F-35 commitment: The Pentagon and Lockheed announced an initial framework for producing 850 F-35 aircraft over 10 years. The agreement provides greater production visibility and could improve supply-chain efficiency, although Lockheed will invest about $7 billion in supporting projects. Pentagon, Lockheed announce agreement for 850 F-35 jets Positive Sentiment: Cash flow and shareholder returns: Lockheed raised its 2026 free-cash-flow outlook to roughly $7.8 billion-$8.0 billion and recently increased its quarterly dividend 4.4% to $3.60 per share. Lockheed Martin, Interactive Brokers, AEP Hike Dividends on Strong Growth Neutral Sentiment: Industry forecasts point to strong growth in defense electronics and land-based C4ISR, potentially expanding Lockheed Martin’s addressable market, but these reports are third-party projections rather than new company contracts. Negative Sentiment: Execution and funding risks remain: The backlog must be converted into deliveries and cash. F-35 deliveries fell year over year, and Lockheed said spending on the Lot 20 advance contract has exceeded currently authorized funding. Higher contract assets and supply-chain constraints could also delay cash collection or pressure margins. Lockheed is spending its own money before Washington signs off (Free Report)

Lockheed Martin Corporation is a global security and aerospace company headquartered in Bethesda, Maryland. Formed in 1995 through the merger of Lockheed Corporation and Martin Marietta, the company develops and produces advanced defense, aerospace, and technology systems for government and commercial customers.

Its principal business areas include Aeronautics, Missiles and Fire Control, Rotary and Mission Systems, and Space. Products and services include military aircraft such as the F-35 Lightning II, C-130 Hercules, and F-16 Fighting Falcon; missile-defense and precision-strike systems; helicopters and naval systems; command, control, communications, and intelligence technologies; satellites; space exploration systems; and other classified space and defense programs.

Lockheed Martin serves the U.S.

Recommended Stories Five stocks we like better than Lockheed Martin Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat Want to see what other hedge funds are holding LMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lockheed Martin Corporation (NYSE:LMT – Free Report).

Receive News & Ratings for Lockheed Martin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lockheed Martin and related companies with MarketBeat.com's FREE daily email newsletter.